

RD-A157 214

NONQUATERNARY CHOLINESTERASE REACTIVATORS(U) SRI  
INTERNATIONAL MENLO PARK CA R A KENLEY ET AL.  
27 JAN 82 DAMD17-79-C-9178

1/1

UNCLASSIFIED


F/G 6/1

NL

END

REMOVED

0TH



MICROCOPY RESOLUTION TEST CHART  
NATIONAL BUREAU OF STANDARDS-1963-A

AD

# NONQUATERNARY CHOLINESTERASE REACTIVATORS

AD-A157 214

## Annual Report

Richard A. Kenley, Robert A. Howd, Carol W. Mosher  
Clifford D. Bedford

January 27, 1982

Supported By  
**U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND**  
Fort Detrick, Frederick, MD 21701-5012

Contract No. DAMD17-79-C-9178

SRI International  
333 Ravenswood Avenue  
Menlo Park, CA 94025-3493



### DoD DISTRIBUTION STATEMENT



Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
	AD-A157 214	
4. TITLE (and Subtitle)	5. TYPE OF REPORT & PERIOD COVERED Annual October 1980 through October 1981	
NONQUATERNARY CHOLINESTERASE REACTIVATORS		6. PERFORMING ORG. REPORT NUMBER PYU-1043
7. AUTHOR(s)	8. CONTRACTOR GRANT NUMBER(s) Richard A. Kenley, Robert A. Howd, Carol W. Mosher, DAMD17-79-C-9178 and Clifford D. Bedford	
9. PERFORMING ORGANIZATION NAME AND ADDRESS SRI International 333 Ravenswood Avenue Menlo Park, CA 94025	10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS 62734A.3M162734A875.AC.421	
11. CONTROLLING OFFICE NAME AND ADDRESS U.S. Army Medical Research and Development Command Ft. Detrick, MD 21701-5012	12. REPORT DATE Jan. 27, 1982	
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)	13. NUMBER OF PAGES 81	
	15. SECURITY CLASS. (of this report) Unclassified	
	15a. DECLASSIFICATION/DOWNGRADING SCHEDULE	
16. DISTRIBUTION STATEMENT (of this Report)  Approved for public release; distribution unlimited.		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES Part I submitted for publication in Journal of Medicinal Chemistry		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) acetylcholinesterase pKa ethyl p-nitrophenyl methylphosphonate in vitro reactivation α-ketothiohydroximates kinetics α-heteroaromatic thiohydroximates mechanism α-heteroaromatic aldoximes QIPRA		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) We prepared a series of dialkylaminoalkyl α-ketothiohydroximates and evaluated them <u>in vitro</u> as reactivators of acetylcholinesterase (AChE) inhibited by ethyl p-nitrophenyl methylphosphonate (EPMP). The compounds conformed to the general formula $4\text{-RH}_2\text{C(O)C(NOH)S(CH}_2\text{)}_n\text{NH}_2\text{-HCl}$ where: R = MeO, n = 2, 3; and R' = $\text{CH}_3$ or $\text{C}_2\text{H}_5$ . For comparison we also examined 2-hydroxy-iminomethyl-1-methylpyridinium iodide (2PAM), $\text{p-BrC}_6\text{H}_4\text{C(O)C(NOH)SCH}_2\text{CH}_2\text{CH}_3$ , and the related α-oximino thiohydroximate $\text{CH}(\text{NOH})\text{C}(\text{NOH})\text{SCH}_2\text{CH}_2\text{NMe-HCl}$ . The thiohydroximates reactivate ethyl methylphosphonyl-AChE via a		

mechanism involving equilibrium binding of reactuator to inhibited enzyme followed by displacement of the inhibitor by reactuator. 2PAM is at least 50 times more reactive toward ethyl methylphosphonyl-AChE than any of the above nonquaternary reactuators. The differences in reactivity apparently relate to entropic factors associated with formation of the reactuator/phosphonylated enzyme complex.


We also prepared a series of oxadiazoles, thiadiazoles, and triazoles with aldoxime or diethylaminoethyl thiohydroximate functional groups. These compounds were characterized with respect to structure, acidity, and activity as reactuators of ethyl methylphosphonyl-AChE. Of seven  $\alpha$ -heteroaromatic aldoximes, only one, 5-hydroxyiminomethyl-3-phenyl-1,2,4-oxadiazole, exhibits an oxime acidity ( $pK_a = 7.9$ ) near the optimal value of  $pK_a = 8$ . This compound is the best nonquaternary AChE reactuator studied to date. 5-Hydroxyiminomethyl-3-phenyl-1,2,4-oxadiazole is three times more active than 4-BrC<sub>6</sub>H<sub>4</sub>C(O)C(NO<sub>2</sub>)SCH<sub>2</sub>CH<sub>2</sub>N(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>·HCl toward ethyl methylphosphonyl-AChE. Several of the  $\alpha$ -oxadiazolyl and  $\alpha$ -thiadiazolyl thiohydroximic acid 2-(diethylamino)ethyl S-esters exhibit acidities near  $pK_a = 8$ . The  $\alpha$ -heteroaromatic thiohydroximates are poorer reactuators of ethyl methylphosphonyl-AChE than 5-hydroxyiminomethyl-e-phenyl-1,2,4-oxadiazole. Again entropic factors apparently limit the activity of the thiohydroximates.

Information for Classification	
U.S.A.I.	<input checked="" type="checkbox"/>
U.S.S.R.	<input type="checkbox"/>
China	<input type="checkbox"/>
Other	<input type="checkbox"/>
Classification Codes	
Standard/Or Int'l	Special
A-1	

## SUMMARY

Pyridinium aldoximes such as 2PAM are effective therapy in poisoning by toxic organophosphorus compounds. However, as quaternary ammonium salts, the pyridinium compounds penetrate poorly from the serum into tissue regions (e.g., the brain) where organophosphorus anticholinesterase elicit pronounced physiological effects. In an effort to develop therapeutics that should surpass the pyridinium aldoximes with respect to tissue distribution, we have synthesized and evaluated various nonquaternary hydroxyimino compounds as reactivators of phosphorylated acetylcholinesterase (AChE).

Our efforts have focused on three general classes of compounds:  $\alpha$ -ketothiohydroximic acid dialkylaminoalkyl S-esters, 1, heteroaromatic aldoximes, 2, and  $\alpha$ -heteroaromatic thiohydroximates, 3.



In each case we characterized the compounds with respect to oxime acid dissociation constant ( $pK_a$ ), structure, and activity in vitro as reactivators of eel AChE inhibited by ethyl p-nitrophenyl methylphosphonate (EPMP).

The in vitro studies on type 1 compounds are essentially complete, but our investigations on types 2 and 3 are continuing. For this reason we have divided the current report into two major sections: Part I describes the preparation and characterization of type 1 compounds and the development of an in vitro model for elucidating structure-activity relationships among novel AChE reactivators. Part II describes progress on type 2 and type 3 compounds.

Part I discusses in detail the use of EPMP-inhibited eel AChE for determining of kinetic parameters for AChE reactivation by 2PAM and type 1 compounds. We demonstrated that under appropriate reaction conditions ethyl methylphosphonyl-AChE does not undergo complicating side reactions (e.g., dealkylation, spontaneous reactivation, enzyme denaturation, enzyme reactivation by phosphoryl oximes) that would otherwise interfere with determining meaningful reactivation kinetics. Of the inhibitor/enzyme combinations tried and reported, we believe the EPMP/eel AChE system to be superior with respect to accurate and convenient determination of kinetics parameters.


We determined kinetic parameters for reactivation of ethyl methylphosphonyl-AChE by type 1 compounds and 2PAM. The kinetics require a mechanism involving reversible formation of a reactivator/inhibited enzyme complex followed by displacement of ethyl methylphosphonate from the enzyme active surface. In terms of inherent activity toward ethyl methylphosphonyl-AChE, 2PAM is 50 to 1000 times more reactive than any of the type 1 compounds investigated. We have interpreted the kinetic data to mean that type 1

compounds and 2PAM bind equally well to the inhibited enzyme but that reactuator/inhibited enzyme complexes derived from 1 have many available conformations, only a small fraction of which feature a geometry suitable for displacing the organophosphorus moiety from the active surface. 2PAM appears to be superior to type 1 compounds not because it is more inherently reactive, but rather because it is more rigid and exhibits a geometry well-suited for reactivation.

We designed our investigation of type 2 and 3 compounds in part to further probe the relationships between reactuator rigidity and activity. We found that the thiohydroximate derivatives, 3, as a class are poorer than type 2 compounds as reactigators of ethyl methylphosphonyl-AChE. This reinforces our hypothesis concerning the need for incorporating structural rigidity into candidate AChE reactigators.

Although none of the nonquaternary reactigators investigated to date equals 2PAM with respect to rate of reactivation of phosphorylated-AChE, several of the new compounds that we have prepared do exhibit reasonable activity as reactigators. Among the most active of the nonquaternary reactigators are:

$\text{BrC}_6\text{H}_4\text{C(O)C(NOH)SCH}_2\text{CH}_2\text{N}(\text{C}_2\text{H}_5)_2 \cdot \text{HCl}$ ,     $(\text{HON:})\text{CHC}(:\text{NOH})\text{SCH}_2\text{CH}_2\text{N}(\text{CH}_3)_2 \cdot \text{HCl}$ ,  
and,



Each of these compounds, at concentrations of  $10^{-4}$  to  $10^{-3}$  M, completely restores activity to ethyl methylphosphonyl-AChE within a few hours. We believe that the currently available nonquaternary reactigators have considerable promise as research tools for probing central nervous system activity of toxic organophosphorus compounds. We further postulate that through appropriate structural modifications it will be possible to obtain nonquaternary reactigators that actually surpass 2PAM in terms of inherent reactivity toward phosphorylated AChE.

In developing new therapeutics it is necessary at some point to evaluate candidate drugs in vitro and in vivo against the specific toxic agents that the drugs are designed to treat. We believe that we have reached this juncture with nonquaternary reactigators. Future work will involve synthesis of new compounds plus evaluation of compounds as reactigators in vitro of AChE inhibited by 3,3-dimethyl-2-butyl methylphosphonofluoride. Furthermore, we recommend that an evaluation of the nonquaternary compounds in vivo versus various toxic organophosphonates be undertaken.

## CONTENTS

<b>Summary .....</b>	<b>3</b>
<b>List of Figures .....</b>	<b>6</b>
<b>List of Tables .....</b>	<b>7</b>
<b>Part I.        <math>\alpha</math>-Ketothiohydroximates as Reactivators of Ethyl Methylphosphonyl-Acetylcholinesterase</b>	
<b>INTRODUCTION .....</b>	<b>9</b>
<b>RESULTS AND DISCUSSION .....</b>	<b>12</b>
<b>Synthesis and Structure .....</b>	<b>12</b>
<b>Control Experiments .....</b>	<b>15</b>
<b>Reactivation Kinetics .....</b>	<b>19</b>
<b>Structure-Activity Relationships .....</b>	<b>30</b>
<b>CONCLUSIONS .....</b>	<b>32</b>
<b>EXPERIMENTAL DETAILS .....</b>	<b>34</b>
<b>ACKNOWLEDGEMENT .....</b>	<b>37</b>
<b>LITERATURE CITED .....</b>	<b>39</b>
<b>Part II.        Heteroaromatic-Oximes and Thiohydroximates as Reactivators of Ethyl Methylphosphonyl-AChE In Vitro</b>	
<b>INTRODUCTION .....</b>	<b>43</b>
<b>RESULTS AND DISCUSSION .....</b>	<b>46</b>
<b>Synthesis and Structure .....</b>	<b>46</b>
<b>Acetylcholinesterase Reactivation .....</b>	<b>55</b>
<b>CONCLUSIONS AND FUTURE WORK .....</b>	<b>61</b>
<b>EXPERIMENTAL DETAILS .....</b>	<b>64</b>
<b>LITERATURE CITED .....</b>	<b>79</b>

## FIGURES

### PART I

1	Reactivation of Ethyl Methylphosphonyl-AChE by 0.010 mM <u>4</u> at 37°C as a Function of Total Enzyme Concentration in the Incubation Solution .....	20
2	Reactivation of Ethyl Methylphosphonyl-AChE by Various Concentrations of 3:0.030 mM <u>3</u> .....	21
3	Semilogarithmic Plot of (100 - % Reactivation) versus Incubation Time for Reaction of Ethyl Methylphosphonyl-AChE with Compounds <u>1b</u> , <u>1c</u> , <u>2</u> , and <u>3</u> .....	25
4	Reciprocal Observed Rate Constant for Reactivation, $(k_{obs})^{-1}$ , versus Reciprocal Oximate Concentra- tion for Reactivation of Ethyl Methyl Phosphonyl- AChE by Various Compounds .....	29

### PART II

1	Oxime Proton NMR Chemical Shift versus $pK_a$ for Various Compounds .....	54
---	--	----

## TABLES

### PART I

1	Selected Data for Thiohydroximates .....	13
2	Spontaneous Reactivation of Ethyl Methylphosphonyl-AChE at Three Concentrations of Total Enzyme .....	18
3	Observed Pseudo-First-Order Rate Constants ( $k_{obs}$ ) and Related Data for Reactivation of Ethyl Methylphosphonyl- AChE by Various Test Compounds .....	23
4	Rate Constants for Reactivation of Ethyl Methylphosphonyl- AChE by Various Test Compounds at 25°C, pH 7.6 .....	27

### PART II

1	Selected Data for Heteroaromatic Aldoximes .....	47
2	Selected Data for $\alpha$ -Heteroaromatic Thiohydroximates .....	50
3	Percent Reactivation ( $ZR_t$ ) of Ethyl Methylphosphonyl- AChE After Incubation with Reactivators at Various Concentrations at 25°C, pH 7.6 .....	57
4	Apparent Bimolecular Rate Constants ( $k_{app}$ ) for Reactivation of Ethyl Methylphosphonyl-AChE at 25°C, pH 7.6 .....	60
5	Kinetic Parameters for Reactivation of Ethyl Methyl- phosphonyl-AChE at 25°C, pH 7.6 .....	62

Part I  $\alpha$ -Ketothiohydroximates as Reactivators of Ethyl Methylphosphonyl-Acetylcholinesterase

INTRODUCTION

Biologically-active organophosphorus compounds are widely used in agriculture and medicine.<sup>1-7</sup> Certain highly toxic organophosphonates are also stockpiled for use in war.<sup>8-10</sup> The potential for deliberate or accidental poisoning by organophosphorus esters dictates a requirement for safe and effective therapeutics.

Most toxic organophosphorus esters are irreversible inhibitors of acetylcholinesterase (acetylcholine hydrolase, EC 3.1.1.7) AChE.<sup>1,11-13</sup> The inhibition proceeds via phosphorylation\* of a serine hydroxyl at the "esteratic" region of the enzyme active site. Conventional therapy of organophosphorus ester intoxication entails coadministration of atropine [to antagonize the effects of accumulated acetylcholine (ACh)] and AChE "reactivators" that restore activity to the enzyme.<sup>14-17</sup> Currently, pyridinium oximes are the only clinically used reactivators. Examples are 2-hydroxyiminomethyl-1-methylpyridinium iodide (2PAM) and 1,3-bis(4-hydroxyiminomethyl-1-pyridinium)propane dibromide (TMB4).

Pyridinium oximes can reactivate AChE because of two factors: an oxime acid dissociation constant ( $pK_a$ ) equal to approximately 8; and a cationic moiety (the  $n$ -alkyl pyridinium ion) at the appropriate distance from the oxime to give a structural similarity to ACh. The oxime acid dissociation constant contributes to a high proportion of the anionic (oximate) form of the reactivator at physiological pH. The oximate acts as a nucleophile to displace the organophosphorus moiety from the serine hydroxyl. The cationic moiety interacts electrostatically with an aspartic acid carboxylate at the "anionic" region of the enzyme active site and affords reversible binding of reactivator to the inhibited enzyme. The geometry of the pyridinium oximes places the oximate close to the phosphorylated serine so that the nucleophilic displacement reaction proceeds readily.


Although the pyridinium oximes are useful therapeutics, the quaternary ammonium functional group common to this class of compounds limits their antidotal activity insofar as the hydrophilic pyridinium cations penetrate

---

\*We use the term "phosphylation" when we do not distinguish between "phosphonylation" and "phosphorylation."

membranes poorly. This causes a disproportionately high serum concentration of the pyridinium reactivators, rapid renal elimination, and marginal antidotal activity in regions (such as the central nervous system) where organophosphorus esters elicit pronounced physiological responses.

In principle, it should be possible to develop nonquaternary AChE reactivators that would not only equal the pyridinium oximes inherent activity toward phosphorylated AChE but that would exhibit a tissue distribution more like that of hydrophobic organophosphorus esters. We earlier<sup>8</sup> investigated series of  $\alpha$ -ketothiohydroximic acid S-esters, given by the general formula, 1:




1

where: R was chosen to "fine-tune" the oxime  $pK_a$ ; the tertiary amine functional group was incorporated to facilitate penetration into hydrophobic tissues while also providing coulombic interaction (via the protonated ammonium salt) with the anionic region of the enzyme active site; and n was varied to optimally separate the cationic and nucleophilic moieties of the reactivator.

In the previous communication we reported the synthesis of nine structurally related  $\alpha$ -ketothiohydroximates and characterized them with respect to structure, acidity, nucleophilicity, and activity in vitro as reactivators of diisopropyl phosphoryl-AChE. These were moderately active reactivators and we tried to quantitatively compare their activity by determining reactivation kinetics. Unfortunately, diisopropyl phosphoryl-AChE undergoes a side reaction (dealkylation, see below) with a rate comparable to the reactivation reaction. This introduced uncertainty into our determination of reactivation kinetics and thwarted further attempts to establish quantitative structure-activity relationships.


To resolve these issues we have now examined the activity of five thiohydroximates as reactivators of ethyl methylphosphonyl-AChE in vitro. Our objectives were to develop a useful in vitro model to accurately determine kinetics of reactivation, and to establish structure-activity relationships for the thiohydroximates as reactivators.

This report describes the synthesis of: 2-(diethylamino)ethyl p-bromo-benzoylthiohydroximate (Code SR 3018), 1a (R = Br, n = 2, R' = C<sub>2</sub>H<sub>5</sub>); 3-(dimethylamino)propyl p-bromobenzoylthiohydroximate, 1d (R = Br, n = 3, R' = CH<sub>3</sub>; the related compounds n-propyl p-bromobenzoylthiohydroximate, 2:



2

and 2-(dimethylamino)ethyl thioglyoximate, 3:





3

We also detail our evaluation of selected thiohydroximates as reactivators in vitro of AChE inhibited by ethyl *p*-nitrophenyl methylphosphonate (EPMP). For comparison, we examined the activity of 2-hydroxyiminomethyl-1-methyl-pyridinium iodide, 4 as a reactivator of EPMP-inhibited AChE.

## RESULTS AND DISCUSSION



### Synthesis and Structure

Table 1 shows structures and pertinent data for compounds used in the current investigation. We prepared the new compounds 1a, 1d, and 2 as previously described<sup>18</sup> for 1b and 1c via reaction (1) and (2):



1 and 2

We obtained the thioglyoximate, 3, by chlorination of glyoxime followed by esterification with 2-(dimethylamino)ethane thiol, reactions (3) and (4):



3

We previously showed that for various 1, oxime acidity correlated well with  $=\text{NO}-\text{H}$  proton NMR chemical shift. Combining data for 1a, 1d, 2, 3, and glyoxime ( $\text{pK}_a = 9.9$ , NMR =  $11.62 \delta$ ) with data previously obtained<sup>18</sup> for  $\alpha$ -ketothiohydroximates gives equation (5):

$$\text{pK}_a = (28.6 \pm 1.2) - (1.62 \pm 0.096)\delta \quad (5)$$

Table 1  
SELECTED DATA FOR THIOHYDROXIMATES

Compound	Structure	$pK_a$	NMR <sup>b</sup> (NO-H) $\delta$ , ppm	Reference
<u>1a</u>	4-BrC <sub>6</sub> H <sub>4</sub> C(O)C(NOH)SCH <sub>2</sub> CH <sub>2</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> •HCl	7.44	13.01	this work
<u>1b</u>	4-MeOC <sub>6</sub> H <sub>4</sub> C(O)C(NOH)SCH <sub>2</sub> CH <sub>2</sub> N(C <sub>2</sub> H <sub>5</sub> ) <sub>2</sub> •HCl	7.82	12.69	19
<u>1c</u>	4-MeOC <sub>6</sub> H <sub>4</sub> C(O)C(NOH)SCH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub> •HCl	8.42	12.50	19
<u>3</u>	(HON)CHC(NOH)SCH <sub>2</sub> CH <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub> •HCl	8.37	12.47(br)	this work


<sup>a</sup>Determined spectrophotometrically in 0.1 M phosphate buffer.

<sup>b</sup>Relative to TMS in DMSO-d<sub>6</sub>.

Similarly for 1 with  $n = 2$ ,  $R' = C_2H_5$ , and  $R = NO_2$ ,  $H$ ,  $MeO$ , and  $Br$ , the  $pK_a$  data of Table 1 and reference 18 correlate with the Hammett substituent constant  $\sigma_p^{19}$  to give equation (6):

$$pK_a = (7.61 \pm 0.005) - (0.78 \pm 0.01)\sigma_p \quad (6)$$


On the basis of IR spectral data, we previously proposed an E-configuration for  $\alpha$ -ketothiohydroximates with six-center intramolecular hydrogen bonding of the hydroxyimino proton to the  $\alpha$ -carbonyl group. Compounds (1a) and (2) should also exist in the E-configuration.



E- $\alpha$ -Ketothiohydroximate

JA-1043-140

The NMR spectrum of 3 exhibited two hydroxyimino proton signals: a broad resonance centered at 12.4 ppm and a sharp peak at 11.84 ppm. The methine  $=C-H$  proton resonance for 3 was centered at 7.80 ppm. By comparison, the NMR of glyoxime in  $DMSO-d_6$ <sup>20</sup> shows hydroxyimino protons at 11.62 and methine protons at 7.83 ppm. These data suggest that one of the hydroxyimino protons in 3 is internally hydrogen bonded and that the other retains the same configuration as in glyoxime. A structure consistent with these data is the E, E-thiohydroximate:










E,E-Configuration for 3

JA-1043-141

Control Experiments

The inhibition of AChE by EPMP and subsequent reactions of ethyl methylphosphonyl-AChE in the presence or absence of oximate reactivators are described by equations (7) through (15):





Equations (7) and (8) show the reaction of enzyme (EOH) with EPMP to yield ethyl methylphosphonyl-AChE, EOP(O)Me(OC<sub>2</sub>H<sub>5</sub>). The designations R<sub>p</sub>- and S<sub>p</sub>- in equations (7) and (8) refer to the stereochemical configuration about the chiral phosphorus atom in EPMP. By analogy with other chiral phosphonate esters<sup>20-23</sup>, one isomer of EPMP (probably the R<sub>p</sub>- enantiomer) should inhibit AChE more rapidly than the other isomer. For clarity, in reactions (9) through (15) we have omitted designations for the stereoisomers of EPMP and its derivatives.

Reaction (9) shows formation of phosphonyl oxime, C<sub>2</sub>H<sub>5</sub>O(Me)P(O)OX, by direct reaction of EPMP with the oximate form of a reactivator (OX).

Reactions (10) and (11) are unimolecular reactions of inhibited (or uninhibited) enzyme. Reaction (10) is the spontaneous reactivation process and reaction (11) includes any nonspecific reactions that lead to uncoverable loss of enzyme activity. Reaction (12) shows dealkylation of ethyl methylphosphonyl-AChE to a species, EOP(O)(Me)OH, that cannot be reactivated by oximates.

As shown in reaction (13), the reaction of oximate with inhibited enzyme proceeds via reversible formation of an oximate/inhibited enzyme complex, [EOP(O)(Me)OC<sub>2</sub>H<sub>5</sub>•OX], followed by nucleophilic attack on phosphorus to yield active enzyme and phosphonyl oxime. Phosphonyl oxime, in turn, partitions between two pathways: reinhibition of AChE [reaction (14)] or hydrolytic decomposition to noninhibitory products [reaction (15)].

Finally, reaction (16) is the acid-base equilibrium between oximate and oxime (HOX).

The scheme given by reactions (7) through (16) demonstrates the complexity of the AChE-inhibitor-reactivator system. Reactivation kinetics can be accurately determined and meaningfully interpreted only when reaction (13) greatly predominates reactions (9) through (12), (14) and (15).

We originally chose to investigate EPMP as an inhibitor because ethyl methylphosphonyl-AChE reportedly<sup>24</sup> undergoes reactions (10) and (12) very slowly. We planned to circumvent problems associated with reaction (7) and the presence of unreacted inhibitor by adding EPMP to a slight excess of the enzyme. We recognized that reactions (8), (9), and (14) could introduce complicating factors but anticipated that reaction (13) would predominate under conditions of high reactivator concentration and low enzyme concentration. Under such conditions, reaction (13) is first-order in [AChE] and

pseudo-zero-order in [OX]. Reaction (8) and (14), however, are second-order overall, i.e., first-order in [AChE] and also first order in  $[S_p\text{-C}_2\text{H}_5\text{O}(\text{Me})\text{P}(\text{O})\text{C}_6\text{H}_4\text{NO}_2]$  or in  $[\text{C}_2\text{H}_5\text{O}(\text{Me})\text{P}(\text{O})\text{OX}]$ , respectively. Thus low enzyme concentrations should favor reaction (13).

To determine the accuracy of these expectations we first measured enzyme activities under different reaction conditions and at different time points. The values determined were:

$A_0$  = uninhibited AChE activity

$A_t$  = AChE activity at time t

$A_{\max}(t \text{ min})$  = maximal AChE activity observed ( $t$  = duration of experiment)

$A_I$  = AChE activity after addition of EPMP

The first step was to determine the concentration of EPMP that would inhibit various levels of purified eel AChE to approximately 5% of original activity. For a solution of AChE at a nominal concentration of 65 ACh units- $\text{mL}^{-1}$ , incubation with 0.40  $\mu\text{M}$  of EPMP yielded maximal inhibition (12% of original activity) within 30 to 60 min. A rough estimate of the rate of the inhibition reaction gave  $k_7 \sim 3 \times 10^5 \text{ M}^{-1} \text{ min}^{-1}$  at 25°C.

We next examined spontaneous reactivation of inhibited enzyme, reaction (10), as a function of enzyme concentration at 37°C. We inhibited a stock solution of 62.5 ACh U. $\text{mL}^{-1}$  AChE to approximately 5% of original activity. The stock solution of inhibited enzyme was then diluted to three different concentrations (3.13, 0.625, and 0.125 ACh U. $\text{mL}^{-1}$  of total AChE, and incubated for time intervals. We withdrew aliquots from each incubation solution and diluted the aliquots into substrate solution for assay of activity, choosing the final aliquot volumes and dilution factors to give identical concentrations of total enzyme in the assay solution for all three incubation solutions. In this experiment we determined rate constants for spontaneous reactivation according to equation (17):

$$\ln(A_I) = k_{10} \cdot t \quad (17)$$

The results in Table 2 show that both the rate of reaction (10) and the maximal activity observed after 1440 min incubation of inhibited enzyme varied inversely with the concentration of total enzyme in the incubation solution. This indicates that some EPMP remained in solution (probably the less reactive  $S_p$ -enantiomer) after the initial rapid inhibition of the stock enzyme solution and that at long reaction times additional enzyme inhibition [reaction (8)] competed with reaction (10).

To probe the effects of enzyme level on reactivation of ethyl methyl-phosphonyl-AChE by oximates, we repeated the above experiment, diluting the stock solution of inhibited enzyme to three concentrations into 0.010 mM 4.

Table 2  
SPONTANEOUS REACTIVATION OF ETHYL METHYLPHOSPHONYL-AChE AT  
THREE CONCENTRATIONS OF TOTAL ENZYME

Total [AChE] <sup>a</sup> <u>ACh-U.-mL<sup>-1</sup></u>	<u>A<sub>0</sub><sup>b,c</sup></u> <u>μM-min<sup>-1</sup></u>	<u>A<sub>I</sub></u> <u>μM-min<sup>-1</sup></u>	<u>A<sub>max</sub></u> (t = 1440 min) <u>μM-min<sup>-1</sup></u>	<u>k<sub>10</sub><sup>d</sup></u> <u>min<sup>-1</sup> × 10<sup>3</sup></u>
0.125	12.5	0.676	3.31	0.85 ± 0.1
0.625	12.5	0.875	2.53	0.45 ± 0.69
3.13	12.5	0.548	1.43	0.35 ± 0.21

<sup>a</sup>Total [AChE] in incubation solution.

<sup>b</sup>AChE activity in assay solution. Not equal to AChE activity in incubation solution.

<sup>c</sup>For definition of symbols, see text.

<sup>d</sup>Calculated according to Equation (17), k<sub>10</sub> is the observed rate constant for spontaneous reactivation.

As before, we withdrew aliquots at timed intervals for assay, choosing aliquot volumes to give the same level of total enzyme in all three assay solutions.

Figure 1 shows the results of this experiment, and illustrates two important points. First, the rates of oximate-induced reactivation varied inversely with the level of enzyme in the incubation solution. Second, at the lowest AChE concentration investigated, 4 completely restored AChE activity to control (uninhibited) values.

The effect of AChE level on reactivation rates indicates that reinhbition of the enzyme by phosphonyl oxime [reaction (14)] was significant only at the two higher AChE concentrations. At the 0.125-ACh U. $\cdot$ mL $^{-1}$  level of AChE, enzyme reactivation [reactions (13) and (15)] predominated over the reinhibition reaction, and for this reason we performed all subsequent reactions at the 0.125-ACh U. $\cdot$ mL $^{-1}$  level. The complete restoration of AChE activity by 4 also demonstrated that dealkylation [reaction (12)] was slow compared with reaction (13). We further proved the unimportance of reaction (12) in a separate experiment by incubating ethyl methylphosphonyl-AChE for timed intervals at 25°C before adding the inhibited enzyme to 1.0 mM 4 and assaying for activity after reactivating the enzyme. In this experiment, 4 reactivated AChE to 106% and 93% of uninhibited enzyme activity after pre-incubation periods, respectively of 6 and 28 h.

As a final control, we studied the oximate-induced reactivation of ethyl methylphosphonyl-AChE as a function of time and concentration of added 3. For comparison we also monitored spontaneous reactivation in the absence of added 3 and the loss of activity of uninhibited enzyme.


Figure 2 shows the results of this experiment and demonstrates that rates of uninhibited enzyme denaturation and spontaneous reactivation of inhibited AChE were slow compared with oximate-induced reactivation. As with 4, reactivation with high concentrations of 3 totally restored AChE activity to control values.

In summary, appropriate control experiments have demonstrated that under suitable reaction conditions the oximate-induced reactivation of ethyl methylphosphonyl-AChE proceeds to the virtual exclusion of complicating side reactions. The EPMP-inhibited eel AChE system appears to be ideally suited to determination of reactivation kinetics. Accordingly, we examined rates of reactivation of ethyl methylphosphonyl-AChE as a function of concentration of added 1, 2, 3, and 4. The following section describes the results of this investigation.

#### Reactivation Kinetics


Incubation of ethyl methylphosphonyl-AChE with a large excess of reactant restores enzyme activity according to pseudo-first-order kinetics, equation (18):

$$\ln(100-R) = k_{obs} \cdot t \quad (18)$$



JA-1043-19

**FIGURE 1 REACTIVATION OF ETHYL METHYLPHOSPHONYL-AChE BY 0.010 mM 4 AT 37°C AS A FUNCTION OF TOTAL ENZYME CONCENTRATION IN THE INCUBATION SOLUTION**  
 (Error bars indicate means  $\pm$  S.E. for  $n = 4$  determinations.)



JA-1043-18

**FIGURE 2 REACTIVATION OF ETHYL METHYLPHOSPHONYL-AChE BY VARIOUS CONCENTRATIONS OF 3: 0.030 mM 3,**

○—○ ; 0.10 mM 3, □—□ ; 0.20 mM 3,  
 △—△ ; 0.60 mM 3, ○—○ ; NO ADDED 3,  
 X—X ; UNINHIBITED AChE, —●—● .

where:

$k_{obs}$  = observed first-order rate constant  
for reactivation

R = percent reactivation  
=  $100(A_t - A_I)/(A_c - A_I)$

$A_c$  = control AChE activity  
=  $A_o$  or  $1/2 A_o + A_{max}$  [for 4] ,

and  $A_t$  and  $A_I$  are as defined in the preceding section.

We determined reactivation kinetics for 4 and for the compounds listed in Table 1. The exact procedure is described in the experimental details section. Briefly, we incubated EPMP with a slight excess of AChE for 20 min to produce ethyl methylphosphonyl-AChE. The inhibited enzyme was then diluted into solutions containing various concentrations of reactigators, and aliquots were withdrawn at timed intervals for assay of activity. In each experiment involving a nonquaternary reactigator, we included at least one concentration of 4 to serve as a standard. In experiments where  $A_{max}$  for reactivation by 4 was nearly identical to  $A_o$ , we defined control activity,  $A_c$ , as the mean value of  $A_o$  and  $A_{max}$ . In cases where reactivation by 4 did not go to completion within the duration of the experiment we set  $A_c$  equal to  $A_o$ . Spontaneous denaturation of AChE was negligible in all cases studied. In calculating values for R, we corrected for any contribution to observed activity due to spontaneous reactivation. To do this, we directly determined  $A_I$  values at each time point for the experiment and used these values to calculate R.

Table 3 summarizes  $k_{obs}$  values and other pertinent data for the kinetic experiments. For most runs, the reaction kinetics adhered well to equation (18); semi-logarithmic plots of  $(100 - R)$  versus time were typically linear to 90% reactivation for experiments that were followed to high conversion. Figure 3 shows typical data plotted according to equation (18) for several of the test compounds. For clarity, not all of the kinetic runs are plotted in Figure 3. In most runs spontaneous reactivation was negligible compared with oximate-induced reactivation. For some relatively poor reactigators at low concentrations, spontaneous and induced reactivation proceeded at comparable rates, but the contribution due to spontaneous hydrolysis could be accurately subtracted.

To relate observed reactivation kinetics to the mechanism for reactivation shown in reaction (13) we treated the data of Table 3 according to equation (19):

$$(k_{obs})^{-1} = \frac{k_r}{k_r} [OX]^{-1} + \frac{1}{k_r} \quad (19)$$

Table 3

OBSERVED PSEUDO-FIRST-ORDER RATE CONSTANTS ( $k_{obs}$ ) AND RELATED DATA<sup>a</sup> FOR  
REACTIVATION OF ETHYL METHYLPHOSPHONYL-ACID BY VARIOUS TEST COMPOUNDS

Experiment	Test Compound <sup>b</sup>	[HOX] <sup>c</sup>	$A_0$ , <sup>c</sup>	$A_{I^*}$ , <sup>c</sup>	$A_{max}(t)$ <sup>e</sup>	$A_c$ , <sup>c</sup>	$k_{10}$ , <sup>f</sup>	$k_{11}$ , <sup>g</sup>	$k_{obs}$ , <sup>h</sup>
		nm	$\mu\text{M min}^{-1}$	$\mu\text{M min}^{-1}$	$\mu\text{M min}^{-1}$	$\mu\text{M min}^{-1}$	$\text{min}^{-1} \times 10^3$	$\text{min}^{-1} \times 10^3$	$\text{min}^{-1} \times 10^3$
1	<u>1a</u>	0	9.19	1.99	--	9.19	0.34	0.064	--
		0.0300	4.31(20)	8.68					1.63 ± 0.039
		0.100		10.7					7.04 ± 0.081
		0.300		9.34					17.8 ± 0.81
2	<u>4</u>	1.00	6.16						21.6 ± 0.41
		0.00150							3.58 ± 0.41
		0	11.9	0.397	--	11.7	1.2	< 0.05	--
		0.0600	6.63(300)	8.97					2.48 ± 0.11
3	<u>1b</u>	0.200		11.0					4.43 ± 0.29
		0.500		11.5					11.8 ± 1.0
		0.0100		11.5					18.2 ± 1.8
		0	12.3	1.94	--	12.3	0.39	0.11	--
4	<u>23</u>	0.0300	1.44(300)	3.25					0.398 ± 0.026
		0.100		5.84					1.22 ± 0.046
		0.300		7.00					1.22 ± 0.18
		1.00		6.75					4.15 ± 0.45
5	<u>4</u>	0.00150							3.43 ± 0.40
		0	10.5	0.243	--	10.7	2.2	< 0.02	--
		0.0300	2.13(360)	1.69					0.507 ± 0.024
		0.100		4.04					0.380 ± 0.0082
6	<u>1c</u>	0.300		5.66					1.23 ± 0.037
		1.00		10.8					2.07 ± 0.045
		0.0100		4.83					23.7 ± 4.3
		0	9.27	0.191	--	9.27	1.8	--	--
7	<u>1d</u>	0.00300	0.323(300)	0.640					0.0680 ± 0.0086
		0.0100		4.83					0.223 ± 0.018
		0.100							2.21 ± 0.018
		0	0	12.4	0.265	--	12.4	2.9	--
8	<u>4</u>	0.500		1.78(300)					0.362 ± 0.028
		1.00		2.43					0.581 ± 0.044
		2.00		2.74					0.664 ± 0.035
		3.00 <sup>1</sup>		1.51					0.728 ± 0.082
9	<u>4</u>	0.00150		7.71					2.98 ± 0.20

Table 3 (concluded)

OBSERVED PSEUDO-FIRST-ORDER RATE CONSTANTS ( $k_{obs}$ ) AND RELATED DATA<sup>a</sup> FOR REACTIVATION OF ETHYL METHYLPHOSPHONYL-ACHE BY VARIOUS TEST COMPOUNDS

Experiment	Test Compound <sup>b</sup>	[HOX] <sup>c</sup>	$A_o$ , nM	$A_I$ , $\mu M \text{ min}^{-1}$	$A_{max}(t)^e$ $\mu M \text{ min}^{-1}$	$A_c^f$ $\text{min}^{-1} \times 10^3$	$k_{10}^g$ $\text{min}^{-1} \times 10^3$	$k_{11}^h$ $\text{min}^{-1} \times 10^3$	$k_{obs}^h$ $\text{min}^{-1} \times 10^3$
7	<u>3</u>	0	25.3	1.21	—	25.0	2.3	0.046	—
		0.0300			15.4(360)				2.26 ± 0.0345
		0.100			22.2				5.60 ± 0.12
		0.200			24.5				15.9 ± 0.41
		0.600			23.4				33.4 ± 3.3
		0.0100			24.7				18.3 ± 4.4
8	<u>4</u>	0	11.5	0.195	—	9.56	0.77	—	—
		0.00050			3.67(360)				1.36 ± 0.14
		0.00150			6.60				3.06 ± 0.25
		0.00400			8.53				9.15 ± 0.91
		0.0100			8.68				23.7 ± 3.4

<sup>a</sup> $k_{obs}$  = observed first-order rate constants for reactivation

= percent reaction

$$= 100(A_t - A_I)/A_c - A_I)$$

$A_c$  = control AChE activity

$A_c = A_o$  or  $1/2 [A_o + A_{max}(\text{for } \underline{4})]$ .

See Table 1 for structures.

<sup>c</sup> [HOX] = concentration of added test compound.

<sup>d</sup> Reported value of  $A_I$  calculated at  $t = 0$  from the intercept of least-squares linear regression of  $A_I$  data according to equation (17).


<sup>e</sup> All  $A_{max}$  values determined at time,  $t$ , in minutes, given parenthetically for first  $A_{max}$  value in an individual experiment.

<sup>f</sup> Calculated according to equation (17).

<sup>g</sup> Calculated according to the expression  $\ln(A_o) = k_{10} \cdot t$ .

<sup>h</sup> Calculated according to equation (18).

<sup>1</sup> Control experiment showed that 2 at 3 mM inhibits AChE to 92% control activity. Corrected  $A_t$  values for 3 mM 2 were calculated.



JA-1043-20

**FIGURE 3 SEMILOGARITHMIC PLOT OF (100-% REACTIVATION) VERSUS INCUBATION TIME FOR REACTION OF ETHYL METHYLPHOSPHONYL-AChE WITH COMPOUND: 1b, 1c, 2, AND 3.**

○—○; 1c, □—□; 2, ●—●; 1b, △—△; 3

where  $[OX]$  is the concentration of oximate ion at pH 7.6, calculated from the concentration of added test compound,  $[HOX]$  as in equation (20)

$$[OX] = [HOX] \{1 + \text{antilog}[pK_a - 7.6]\}^{-1} \quad (20)$$

The derivation of equation (19) is straightforward and has been described elsewhere.<sup>25-28</sup> We used the concentration of oximate (as opposed to  $[HOX]$ ) in equation (20) because the protonated form of the oxime is essentially unreactive as a nucleophile or as a reactivator.

According to equation (19), a plot of  $(k_{\text{obs}})^{-1}$  versus  $[OX]^{-1}$  is linear with slope  $= K_r/k_r$  and intercept  $= 1/k_r$ . Such plots therefore permit the calculation of the individual rate constants for reactivation,  $k_r$  and  $K_r$ . It can also be shown,<sup>27-28</sup> that in the limit of low reactivator concentration ( $[OX] \ll K_r$ ) the ratio of  $k_r$  to  $K_r$  is equivalent to an apparent bimolecular rate constant for reactivation, i.e.:

$$k_r/K_r = k_b \quad (21)$$

The bimolecular reactivation rate constant,  $k_b$ , is a measure of the inherent activity of an oximate as a reactivator of the inhibited enzyme. Because various oximes and thiohydroximates ionize to different extents at pH 7.6, we define an effective rate constant for reactivation of inhibited AChE as the product of  $k_b$  and the fraction of added test compound present as oximate at pH 7.6, i.e.,

$$k_{\text{eff}} = k_b [1 + \text{antilog}(pK_a - 7.6)]^{-1} \quad (22)$$

Table 4 summarizes values for reactivation rate constants calculated from the data of Table 3 using equations (19) through (22). Figure 4 is a double-reciprocal plot of the data according to equation (19) for 1a through 1c, 2, and 3. Figure 4 does not show data for 1d and 4 because of the differences in scale. In examining Table 4, it may be helpful to recall that  $K_r$ , by definition, equals  $[OX][EOP(0)(Me)OC_2H_5]/[EOP(0)(Me)OC_2H_5 \cdot OX]$  and that a low value for  $K_r$  reflects a high proportion of oximate present as the oximate/inhibited enzyme complex.

Table 4 and Figure 4 demonstrate that the kinetic data conformed well to equation (19). Least-squares linear regression of the data for experiments 1 through 8 gave slopes with reasonably small relative uncertainty. Relative uncertainties were larger in calculations of intercept values, but least-squares correlation coefficients indicated a good fit of the data to equation (19).

Table 4

RATE CONSTANTS FOR REACTIVATION OF ETHYL METHYLPHOSPHONYL-AChE  
BY VARIOUS TEST COMPOUNDS AT 25°C, AT pH 7.6

Compd <sup>a</sup>	[ox] <sup>-1</sup> $M^{-1} \times 10^{-3}$	(k <sub>obs</sub> ) <sup>-1</sup> $M^{-1} \text{min}^{-1}$	Slope <sup>c</sup> $M^{-1} \text{min} \times 10^2$	Intercept <sup>c</sup> $\text{min}$	Correlation <sup>c</sup>		k <sub>r</sub> <sup>d</sup> $\text{min}^{-1} \times 10^3$	k <sub>b</sub> <sup>e</sup> $M \times 10^4$	k <sub>eff</sub> <sup>f</sup> $M^{-1} \text{min}^1$
					Coefficient	min			
<b>1a</b>	0.0300	56.4	613.0	1.05 ± 0.14	41.5 ± 35	0.958	24.1	2.53	95.3
	0.0600	28.2	403.0						56.3
	0.100	16.9	142.0						
	0.200	8.46	226.0						
	0.300	5.64	56.2						
	5.00	3.38	84.7						
<b>1b</b>	0.0300	88.5	2060	2.68 ± 0.052	133 ± 24	0.999	7.52	2.02	37.2
	0.100	26.6	763						14.0
	0.300	8.85	362						
<b>1c</b>	0.100	2.66	212						
	0.300	76.1	2630	3.23 ± 0.36	133 ± 170	0.994	7.52	2.43	30.9
	1.00	25.4	813						4.06
<b>1d</b>	0.00300	715	14700	2.05 ± 0.0082	34.4 ± 35.4	0.999	29.1	5.96	48.8
	0.0100	215	4480						22.8
	0.100	21.5	452						
<b>2</b>	0.500	14.6	2760						
	1.00	7.31	1720	11.4 ± 1.3	1050 ± 113	0.986	0.952	1.09	8.77
	2.00	3.65	1510						1.26
	3.00	2.44	1370						

Table 4 (concluded)

MATE CONSTANTS FOR REACTIVATION OF ERYL METHYLPHOSPHONYL-AChE  
BY VARIOUS TEST COMPOUNDS AT 25°C, AT pH 7.6

Compound <sup>a</sup>	[MX] M	[MX] $\times 10^{-3}$ M	( $k_{obs}$ ) <sup>-1</sup> min <sup>-1</sup> $\times 10^2$	Slope <sup>c</sup> min M <sup>-1</sup>	Intercept <sup>c</sup> min	Correlation <sup>c</sup> Coefficient	$k_r^d$ min <sup>-1</sup> $\times 10^3$	$k_t^d$ M <sup>-1</sup> $\times 10^4$	$k_b^e$ M <sup>-1</sup> $\times 10^4$	$k_{eff}^f$ M <sup>-1</sup> min <sup>-1</sup>
3	0.0300	230	442	0.168 ± 19.7	0.998		61.2	1.15	534	77.4
	0.100	68.9	179	0.0162						
	0.200	34.4	62.9							
	0.500	11.5	29.9							
4	0.000500	6910.0	735	0.0104 ± 24	0.996		36.0	0.0374	9630	2780
	0.00150	2300.0	3078	0.00064						
	0.00400	864.0	109							
	0.0100	345.0	43.5 <sup>b</sup>							

<sup>a</sup>See Table 1 for structures and pK<sub>a</sub> data.


<sup>b</sup>Calculated from equation (20).

<sup>c</sup>From linear least-squares linear regression of data according to equation (19).

<sup>d</sup>From equation (19).

<sup>e</sup>From equation (21).

<sup>f</sup>From equation (22).



JA-1043-17A

FIGURE 4 RECIPROCAL OBSERVED RATE CONSTANT FOR REACTIVATION,  
 $(k_{\text{obs}})^{-1}$ , VERSUS RECIPROCAL OXIMATE CONCENTRATION  
FOR REACTIVATION OF ETHYL METHYLPHOSPHONYL-AChE BY:  
1a,  $\Delta$ — $\Delta$ ; 1b,  $\square$ — $\square$ ; 2,  $\circ$ — $\circ$ ; AND 3,  $\bullet$ — $\bullet$

The precision of the kinetic data demonstrates the general utility of ethyl methylphosphonyl-AChE as an in vitro model for evaluating AChE reactivators. Other inhibitors have been investigated as in vitro models for reactivation but most of the literature models suffer important disadvantages. Examples of phosphorylated AChE's and complicating factors are 3,3-dimethyl-2-butyl methylphosphonyl-AChE (rapid dealkylation<sup>28,29</sup>, incomplete reactivation<sup>30</sup>), cyclopentyl methylphosphonyl-AChE (rapid dealkylation, re inhibition by phosphonyl-oxime<sup>32</sup>), diisopropyl phosphoryl-AChE (rapid dealkylation<sup>20</sup>), ethyl dimethylphosphoramido-AChE (dealkylation<sup>33</sup>, low rates of reactivation<sup>34</sup>) and diethyl phosphoryl-AChE (re inhibition<sup>35,36</sup>).

Similarly, for any in vitro model system, different approaches to determining reactivation kinetics may or may not provide meaningful data. For example, determining percent activity restored to inhibited AChE after incubation with one concentration of reactivator for a single time period is convenient for preliminary screening of novel reactivators,<sup>37,38</sup> but cannot be used to calculate reactivation rates. Determination of observed pseudo-first-order rate constants for reactivation at a single concentration of reactivator is sometimes used to calculate bimolecular rate constants, assuming a simple second-order kinetic expression for the reactivation reaction.<sup>39-41</sup> However this assumption is clearly invalid in view of the well-established<sup>25-28</sup> mechanism for reactivation shown in reaction (13). It is also invalid to calculate rate constants for reactivation according to equation (19) if re inhibition of the enzyme by phosphonyl oxime is demonstrably important under the experimental conditions used.<sup>42</sup>

In summary there is a definite need for a well-characterized in vitro model system for determining kinetics of reactivation of phosphorylated-AChE. Of the many systems described in the literature few, if any, are wholly satisfactory. By contrast, ethyl methylphosphonyl-AChE proves to be exceptionally useful for kinetic determinations. Under the conditions that we have chosen, reactivation of ethyl methylphosphonyl-AChE by oximates proceeds without substantial interference from complicating side reactions. The system conforms well to a simple rate expression and accurate reactivation kinetics can be conveniently determined. The inhibitor (EPMP), enzyme (eel AChE), and standard reactivator (4) reported herein are all obtainable conveniently and in high purity and this should facilitate comparison of data obtained in different laboratories using the single model system.

#### Structure-Activity Relationships

Having developed a useful in vitro model, we wished to examine structure-activity relationships for the thiohydroximates. The goal was to relate specific chemical and structural properties of the nonquaternary reactivators to the kinetic constants  $k_r$ ,  $K_r$ , and  $k_b$ . We anticipated, for example, that  $k_r$  values might correlate with the inherent nucleophilicity (and hence to the basicity)<sup>18</sup> of the oximates and that  $K_r$  values would vary with structural changes (such as replacing the diethylamino moiety in 1a with a methyl group, as found in 2).

Surprisingly, however, the individual values of  $k_r$  and  $K_r$  did not vary in a systematic fashion with oximate structure or inherent reactivity. Compounds 2 and 3 for example exhibited identical  $pK_a$  values and the two oximates should feature similar Bronsted nucleophilicities. However, compounds 2 and 3 showed, respectively, the lowest and highest  $k_r$  values of all the reactivators tested.

Similarly we expected 2 to exhibit a distinctly low affinity for inhibited enzyme (and hence an unusually high value for  $K_r$ ) because of all the reactivators reported herein only 2 does not feature a protonated or quaternary amine functionality to provide coulombic interactions with the enzyme anionic region. We found, however, the  $K_r$  value for 2 to be identical (within a factor of two) with  $K_r$  values for 1 and 3.

Thus we conclude that  $k_r$  and  $K_r$  values cannot be considered independently in elucidating structure-activity relationships for AChE reactivators, that  $k_r$  and  $K_r$  are coupled, and that only  $k_b$  values genuinely reflect the reactivity of oximate reactivators.

To date, the literature has not adequately addressed the interdependence of  $k_r$  and  $K_r$  values and the mechanistic implications of our findings deserve further comment. In this regard, it is important to recall that  $K_r$  is not truly a direct measure of the fraction of total oximate bound to the anionic region of the inhibited enzyme. Rather,  $K_r$  derives from observed rate constants for restoration of enzymatic activity, and the value of  $K_r$  therefore only reflects the fraction of bound oximate that contributes to reactivation.

Any molecule (including any oximate/inhibited enzyme complex) exists in a finite number of low energy conformations that are accessible at ambient temperature. For a particular oximate/inhibited enzyme complex only those conformations that feature the =NO<sup>-</sup> moiety suitably positioned to approach phosphorylated serine will result in reactivation. Also, the inherent nucleophilicity of the oximate will determine the rate at which nucleophilic attack on phosphorylated serine proceeds for any conformer of reactivator/inhibited enzyme complex. Thus  $k_r$  and  $K_r$  values depend not only on oximate reactivity but also on geometry of the oximate/inhibited enzyme complex. This interdependence between oximate reactivity and structure necessarily couples  $k_r$  and  $K_r$  values and precludes interpretation of individual values of these constants.

Differences in oximate/inhibited enzyme complex conformations may also explain the generally lower activity of the nonquaternary reactivators compared with 4. Table 4 shows that  $K_r$  for 4 is lower by a factor of approximately  $10^2$  than  $K_r$  values for 1, 2, and 3. In view of the foregoing discussion we do not believe that the low  $K_r$  value for 4 indicates a particularly high affinity of the pyridinium oxime for the inhibited enzyme. Rather, we consider that, as a first approximation, 1, 3 and 4 form oximate/inhibited enzyme complexes equally well. Two observations support this view. First, we observed previously<sup>18</sup> that 1b and its methyl quaternary analog, MeOC<sub>6</sub>H<sub>4</sub>C(O)C(NOH)CH<sub>2</sub>CH<sub>2</sub>N(C<sub>2</sub>H<sub>5</sub>)<sup>+</sup>CH<sub>3</sub>I, do not differ greatly in reactivity toward phosphorylated AChE. Second, Table 4 demonstrates that 2,

which is devoid of an amine functionality, is markedly inferior to 1 and 3 as a reactivator. Thus the protonated dialkylaminoalkyl moiety common to 1 and 3 does provide electrostatic binding of oximate to the inhibited enzyme. Because simple coulombic interactions between the AChE aspartate and the (quaternary or protonated) ammonium functionalities of 1, 3, and 4 should be roughly equivalent, it seems unreasonable to attribute the comparatively high reactivity of 4 to enhanced affinity toward inhibited AChE. Rather, it is likely that the nonquaternary reactivators differ from 4 primarily with respect to conformational degrees of freedom. Because 1 and 3 are rather flexible, we suggest that the nonquaternary reactivators combine with phosphorylated AChE to yield an oximate/inhibited enzyme complex featuring many low-energy conformations, only a small fraction of which have the oximate moiety positioned close to phosphorylated serine. In the case of the more rigid molecule, 4, a higher proportion of oximate/inhibited enzyme complex conformations have geometries that favor nucleophilic attack on phosphorylated serine.

Thus in terms of free energy of activation for reactivation of phosphorylated-AChE, we propose that the nonquaternary reactivators with dialkylaminoalkyl groups and 4 do not exhibit appreciably different enthalpies of activation; the binding affinities are approximately equal in both cases. Rather, the difference in reactivity apparently relate to entropic factors, i.e., to degrees of freedom for the oximate/inhibited enzyme complexes.

## CONCLUSIONS

The search for AChE reactivators for treating organophosphorus ester poisoning has continued unabated for the last 25 years. Despite considerable research in this field surprisingly few investigators have examined details of the in vitro activity of candidate drugs using a well-characterized model system. We believe that accurate determination of reactivation kinetics for structurally related compounds is critical to the rational development of improved therapeutics. Of the many enzyme/inhibitor combinations reported in the literature, we believe the ethyl *p*-nitrophenyl methylphosphonate/eel AChE model system described herein to be the only combination that has been demonstrated to be substantially free of complicating side reactions (such as dealkylation, reinhibition, and spontaneous reactivation) that otherwise interfere with measurement of reactivation kinetics. EPMP is easily synthesized and, though quite toxic, can be safely and conveniently used to prepare inhibited AChE samples for kinetic experiments. We strongly recommend that the ethyl methylphosphonylated eel AChE be considered as a model system for characterization of any experimental AChE reactivators.

The thiohydroximates reported herein proved to be modest AChE reactivators compared with 2-hydroxyiminomethyl-1-methylpyridinium iodide: the thiohydroximates are less reactive towards ethyl methylphosphonyl-AChE by factors of  $10^1$  to  $10^3$ . An examination of structure-activity relationships for the nonquaternary reactivators suggests that entropic factors (as opposed to low affinity for inhibited AChE) limit the activity of the thiohydroximates. We have argued that the thiohydroximates bind strongly to the anionic region of inhibited AchE but that only a relatively small fraction of the low-energy conformations of the reactuator/inhibited enzyme complex feature an oximate/phosphonyl serine geometry suitable for reactivation of the enzyme. Thus we include rigidity with other important factors (such as nucleophilicity, geometry, and cationic functionality) as a requirement for oximate activity in reactivating inhibited AChE.

## EXPERIMENTAL DETAILS

The materials and methods were generally as previously described.<sup>18</sup> In the following we provide information on new compounds and procedures.

Diethyl methylphosphonate (Specially Organics, Inc.), *p*-bromobenzophenone (Aldrich Chemical Co.), and glyoxime (Aldrich) were used as supplied by the manufacturer. Ethyl *p*-nitrophenyl methylphosphonate (EPMP) was prepared by reaction of *p*-nitrophenol with diethyl methylphosphonate and purified by vacuum distillation.<sup>43</sup> CAUTION! EPMP is an extremely toxic anticholinesterase agent. It must be handled with gloves and in a fume hood, or at high dilutions at all times.

2-(Diethylamino)ethyl *p*-bromobenzoylthiohydroximate hydrochloride (1a) was prepared per our previously described method<sup>18</sup> by conversion of *p*-bromoacetophenone to  $\alpha$ -chloro- $\alpha$ -hydroxyimino-*p*-bromoacetophenone followed by esterification with 2-(diethylamino)ethanethiol and treatment with HCl. Yield, 29%; m.p. 161–165°C; TLC,  $R_f$  = 0.58 (CHCl<sub>3</sub>:MeOH, 6:1). NMR (DMSO-d<sub>6</sub>),  $\delta$  13.00 (br. s, 1H, =NOH), 10.64 (br, 1H, NH<sup>+</sup>), 7.80 (m, 4H, Ar), 3.4–2.9 (m, 8H, CH<sub>2</sub>), 1.18 (t, 6H, CH<sub>3</sub>). IR(nujol),  $\nu$ , 2640(s), 1660(s), 1600(s), 985(S) cm<sup>-1</sup>. Anal. C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>Cl<sub>2</sub>.

3-(Dimethylamino)propyl *p*-bromobenzoylthiohydroximate (1d) was prepared as described for 1a, substituting 3-(dimethylamino)propanethiol in the esterification step. Yield, 32%; m.p. 104–106°C; TLC,  $R_f$  = 0.45 (CHCl<sub>3</sub>:MeOH, 6:1). The NMR of 1d in DMSO-d<sub>6</sub> showed no separate resonances for hydroxyimino or oxalic acid protons. However D<sub>2</sub>O exchange removed three proton signals occurring near the aromatic protons at 7.7 ppm. To show the presence of the =NOH proton in 1d, the NMR of the free base of 1d was also determined in CDCl<sub>3</sub>. NMR data in both solvents follow. DMSO-d<sub>6</sub>,  $\delta$  7.80 (m, 7H, Ar, =NOH, oxalate), 2.98 (m, 4H, 2CH<sub>2</sub>), 2.65 (s, 6H, 2CH<sub>3</sub>), 1.7 to 2.0 (m, 2H, CH<sub>2</sub>). CDCl<sub>3</sub>,  $\delta$  11.40 (s, br, 1H, =NOH), 7.73 (q, 4H, Ar), 2.93 (m, 2H, CH<sub>2</sub>), 2.52 (m, 2H, CH<sub>2</sub>), 2.18 (s, 6H, CH<sub>3</sub>), 1.6 to 1.9 (m, 2H, CH<sub>2</sub>). Anal. C<sub>12</sub>H<sub>20</sub>N<sub>2</sub>.

n-Propyl *p*-bromobenzoylthiohydroximate (2) was prepared by esterification of  $\alpha$ -chloro- $\alpha$ -hydroxyimino-*p*-bromoacetophenone with propanethiol after purification by flash and thick layer chromatography in silica gel using CHCl<sub>3</sub>:MeOH (20:1). Yield 15%; m.p. 67–69°C; TLC,  $R_f$  = 0.66 (CHCl<sub>3</sub>:MeOH, 20:1). NMR (DMSO-d<sub>6</sub>)  $\delta$  12.60 (s, 1H, =NOH), 7.81 (m, 4H, Ar), 2.83 (t, 2H, CH<sub>2</sub>), 1.47 (m, 2H, CH<sub>2</sub>), 0.86 (t, 3H, CH<sub>3</sub>); IR (CHCl<sub>3</sub>)  $\nu$ , 3400 (br, m), 1690, (m), 1590, (m), 1220, (s), cm<sup>-1</sup>. Anal. C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>Cl<sub>2</sub>.

2-(Dimethylamino)ethyl thioglyoximate hydrochloride (3) was prepared from monochloroglyoxime.<sup>44</sup> To a solution of crude monochloroglyoxime (2.5 g, ~ 2 x 10<sup>-2</sup> mol) and triethylamine (4.0 g, 4.0 x 10<sup>-2</sup> mol) in 75 mL of CHCl<sub>3</sub> was added 2-(dimethylamino)ethanethiol hydrochloride (2.8 g, 2.0 x 10<sup>-3</sup> mol). A slight exotherm was noted and the mixture was stirred 2 hours at ambient

temperature. The reaction mixture was then concentrated and triturated with two 50 mL portions of diethyl ether. The ether triturations were combined, dried over anhydrous  $MgSO_4$ , and concentrated to yield 2.0 g of oil, containing oxime as indicated by IR. The residue from the trituration was dissolved in water and extracted repeatedly with  $CH_2Cl_2$ . No oxime was evident (IR) in the  $CH_2Cl_2$  extract. The ether triturations were column chromatographed (20%  $CH_3OH$ :80% acetone), and oxime-containing fractions were combined and concentrated, affording an oil insoluble in  $CHCl_3$  and acetone but soluble in  $CH_3OH$  and dimethyl sulfoxide (DMSO). The oil was dissolved in 10 mL DMSO, and 100 mL  $CHCl_3$  was added. The solution was cooled to -20°C and scratched to yield 0.150 g (10%) of a white crystalline precipitate. The solid material exhibited a broad melting point range (55-134°C). This suggests that the compound readily loses water on heating in the melting point apparatus. Consistent with this, the field ionization mass spectrum of lc shows no molecular ion, but a parent peak at mass 141 corresponding to 4-(2-dimethylamino)ethyl-1,2,5-oxadiazole, the product resulting from elimination of HCl and  $H_2O$  from lc. NMR (DMSO-d<sub>6</sub>), δ 12.47 (br, s, 1H, =NOH); 11.84 (s, 1H, CHNOH) 7.80 (s, 1H, CHNOH); 3.33 (m, 4H,  $CH_2$ ) and 2.73 ppm (s, 6H,  $CH_3$ -i). IR (KBr), 3300 (s), 2940 (s), 2700 (s), 1460 (s), 1390 (s) and 955 (s) cm<sup>-1</sup>. Analysis for  $C_6H_{14}N_3O_2SCl$ . Calc'd: C, 31.65; H, 6.20; N, 18.45; S, 14.08; Cl, 15.56. Found: C, 31.64; H, 6.23; N, 18.44; S, 14.08; Cl, 15.56.

Acetylcholinesterase determinations in vitro. Unless otherwise noted, all experiments were conducted at  $25.0 \pm 0.1^\circ C$  in pH 7.6 0.1 M morpholino-propanesulfonic acid (MOPS) buffer plus  $NaN_3$  (0.002%),  $MgCl_2$  (0.01 M) and bovine serum albumin (0.1%). Enzyme activities were assayed by the Ellman method<sup>45</sup> on a Gilford-modified DU Spectrophotometer coupled to a Digital Electronics Corp. MINC-11 laboratory computer for automatic rate determination. All rate constants were determined by least-squares linear regression analysis with error limits reported as standard deviation from the mean.

In general, eel AChE (Worthington) was reacted with the quantity of EPMP giving approximately 90% inhibition of activity in 20 min. Aliquots of inhibited enzyme were then withdrawn and diluted in MOPS buffer containing known concentrations of reactivators. The inhibited enzyme was incubated with reactivators for timed intervals and assayed (in duplicate) for activity. In parallel experiments, uninhibited AChE and inhibited AChE in the absence of added reactivator were assayed for activity to determine respectively, rates of enzyme denaturation and spontaneous reactivation. Control experiments demonstrated that inhibition of AChE by reactivators in the assay solutions and decomposition of reactivators were negligible under the reaction conditions. Observed activities were corrected to net activities by subtracting rates of spontaneous and reactivator-induced substrate hydrolysis.

Dilution factors and aliquot volumes were determined experimentally for the various transfers involved in the experiments. An exact procedure giving good precision in replicate assays is as follows:

Dilute 110  $\mu L$  of (nominally) 500 acetylcholine units (ACh U) per mL of enzyme solution with 110  $\mu L$  MOPS buffer to give enzyme "stock" solution. For determining uninhibited AChE activity, dilute 25  $\mu L$  stock solution to 20 mL MOPS buffer and withdraw 50  $\mu L$  for assay (see below).

To inhibit the AChE, dilute 140  $\mu$ L stock solution in 132  $\mu$ L MOPS plus 8  $\mu$ L of EPMP ( $1 \times 10^{-5}$  M in  $C_2H_5OH$ ). To determine activity of the inhibited AChE, incubate 20 min, withdraw 10  $\mu$ L, and dilute to 4.0 mL in MOPS and assay 50  $\mu$ L.

For reactivation studies, dilute 100  $\mu$ L of inhibited AChE solution to 1.0 mL with MOPS buffer, remove 25  $\mu$ L (for each incubation), and dilute to 1.0 mL with MOPS plus reactivator at known (including zero) concentrations. Remove 50  $\mu$ L for assay.

For assay of AChE activity, add 50  $\mu$ L aliquots of solution to be assayed to 910  $\mu$ L pH 8.0, 0.1 M phosphate buffer plus 30  $\mu$ L of 0.10 M bis-dithionitrobenzoic acid, plus 10  $\mu$ L of 0.075 M acetylthiocholine, and monitor increased absorbance at 412 nm versus time.

#### ACKNOWLEDGEMENT

This work was supported by the US Army Medical Research and Development Command contract DAMD17-79-C-9178. The authors gratefully acknowledge Dr. Brennie Hackley of the US Army Medical Research Institute for Chemical Defense and Dr. Edward Acton of SRI International for many helpful suggestions. We also thank Dorris Taylor of SRI for  $pK_a$  determinations, and Dr. Ronald Fleming for developing the MINC program for enzyme kinetics.

#### LITERATURE CITED

1. Heath, D. F. "Organophosphorus Poisons - Anticholinesterases and Related Compounds" Pergamon Press, New York, 1961.
2. Spear, R. C.; Jenkins, D. L.; Milby, T. H. Environ. Sci. Technol., 1975, 9, 308-313.
3. Milby, T. H. J. Am. Med. Assoc., 1971, 216, 2131-2133.
4. Koller, W. C.; Klawans, H. L. Handb. Clin. Neurol. 1979, 37, 541-52.
5. Baker, E. L.; Warren, Mc.; Zack, M.; Dobbin, R. D.; Miles, J. W.; Miller, S.; Alderman, L.; Teeters, W. R. Lancet, 1978, 1, 31-34.
6. Koelle, G. B. in "The Pharmacological Basis of Therapeutics," L. Goodman and A. Gilman (eds.), MacMillan, New York, 1965; pp. 404-444.
7. Sim, V. M. in "Drill's Pharmacology in Medicine," 3rd Ed., McGraw-Hill, New York, 1965' pp. 971-982.
8. Harris, B. L.; Shanty, F. "Kirk-Othmer Encyc. Chem. Technol.," 3d Ed., Vol. 5, J. Wiley and Sons, New York, 1980; pp. 393-416.
9. Meselson, M.; Robinson, J. P., Sci. Amer., 1980, 242, 39-47.
10. "CB Weapons Today,; in The Problems of Chemical and Biological Warfare, Stockholm International Peace Research Institute, Humanities Press, New York, 1973; Vol. 2, pp. 17-115.
11. Karczmar, A. G. Int. Encycl. pharmacol. Ther., 1970, 1(13), 1-40.
12. Usdin, E. Int. Encycl. Pharmacol. Ther., 1970 1(13), 47-356.
13. Englehard, N.; Prchal, K; Nenner, M. Angew Chem. Internat. Ed., 1967, 6, 615-626.
14. Wills, J. H. Int. Encycl. Pharmacol. Ther., 1970, 1(13), 357-469.
15. Namba, T.; Nolte, C. T.; Jackrel, J.; Grob, D. Am. J. Med., 1971, 50, 475-492.
16. Ellin, R. I.; Wills, J. H. J. Pharmaceut. Sci., 1964, 53, 995-1007.
17. McNamara, B. P. "Oximes as Antidotes in Poisoning by Anticholinesterase Compounds," Edgewood Arsenal Special publication. 5B-SP-76004, avail. NTIS AD-A0/23243, 1976.

18. Kenley, R. A.; Howd, R. A.; Mosher, C. W.; Winterle, J. S. *J. Med. Chem.*, 1981, 24, 1124-1133.
19. Kosower, E. M. "An Introduction to Physical Organic Chemistry," J. Wiley and Sons, New York, 1968, p. 49.
20. Aaron, H. S.; Michel, H. O.; Witten, B.; and Miller, J. I. *J. Am. Chem. Soc.*, 1958, 80, 456-458.
21. Ooms, A.J.J.; Boter, H. L. *Biochem. Pharmacol.*, 1965, 14, 1839-1846.
22. Keijer, J. H.; Wolring, G. Z. *Biochim. Biophys. Acta*, 1969, 185, 465-68.
23. Schoene, K. in "Medical Protection Against Chemical Warfare Agents", Almqvist and Wiksell, Uppsala, 1976, pp. 88-100.
24. Berry, W. K.; Davies, D. R. *Biochem. J.*, 1966, 100, 572-576.
25. Green, A. L.; Smith, H. J. *Biochem. J.*, 1958, 68, 28-31.
26. Green, A. L.; Smith, H. J. *Biochem. J.*, 1958, 68, 32-35.
27. Wang, E.I.C.; Braid, P. E. *J. Biol. Chem.*, 1967, 242, 2683-2687.
28. Schene, K.; Steinhanses, J.; Wertmann, A. *Biochim. Biophys. Acta.*, 1980, 616, 384-388.
29. Michel, H. O.; Hackley, B. E.; Berkowitz, G. L.; Hackley, E. B.; Gillilan, W.; Pandau, M. *Archiv. Biochem. Biophys.*, 1967, 121, 29-34.
30. De Jong, L.P.A.; Wolring, G. Z. *Biochem. Pharmacol.*; 1980, 29, 2379-2387.
31. Keijer, J. H.; Wolring, G. Z.; De Jong, L.P.A. *Biochem. Biophys. Acta.*, 1974, 334, 146-155.
32. DeJong, L.P.A.; Wolring, G. Z. *Biochem. Pharmacol.*; 1978, 29, 2229.
33. DeJong, L.P.A.; Wolring, G. Z. *Biochem. Pharmacol.*; 1978, 27, 2911.
34. Schene, K.; Oldiges, H. *Archiv. Int. Pharmacodyn. Ther.*, 1973, 204, 110-23.
35. Schoene, K.; Strake, E. M. *Biochem. Pharmacol.*, 1971, 20, 1041-1051.
36. Schoene, K., *Biochem. Pharmacol.*, 1972, 21, 163-170.
37. Hagedorn, I.; Stark, I.; Lorenz, H.P. *Angew. Chem. Int. Ed.*, 1972, 11, 307-309.

38. Dirks, V. E.; Scherer, A.; Schmidt, M.; Zimmer, G. *Arzneim.-Forsch.*, 1970, 20, 197-200.
39. Krivenchuk, V. E.; Brizgailo, L. I.; Petrunkin, V. E. *Biokhim.* 1974, 39, 1163-7.
40. Marsimovic, M. *Acta Pharm. Jugoslav.*, 1976, 26, 233-237.
41. Simon, V.; Wilhelm, K.; Granov, A.; Besarovic-Lazarev, S.; Buntic, A.; Fajdetic, A.; Binenfeld, Z. *Archiv. Toxicol.*, 1979, 1, 301-306.
42. Skrinjaric-Spoljar, M.; Kralj, M. *Archiv. Toxicol.*, 1980, 45, 21-27.
43. Fukuto, T. R.; Metcalf, R. L. *J. Am. Chem. Soc.*, 1959, 80, 372-377.
44. Gaudiano, G.; Ricca, A. *Gazz. Chim. Ital.*, 1959, 89, 587.
45. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M.; *Biochem. Pharmacol.*, 1961, 7, 88-95.


Part II. Heteroaromatic Oximes and Thiohydroximates as Reactivators of Ethyl Methylphosphonyl-AChE In Vitro

INTRODUCTION

Organophosphorus compounds are widely used in agriculture, and cases of accidental or deliberate poisoning by these chemicals are commonplace.<sup>1-6</sup> Certain highly toxic organophosphorus esters have also been developed for use in war.<sup>7-10</sup> In the event of armed conflict involving toxic chemicals, mass casualties among civilians are almost certain.<sup>9</sup> Thus development of effective therapy for organophosphorus ester intoxication remains an important area for research.

Typically, toxic organophosphorus esters are irreversible inhibitors of acetylcholinesterase (acetylcholine hydrolase, EC 3.1.1.7) AChE.<sup>11-13</sup> The inhibition proceeds via phosphorylation<sup>14</sup> of a serine hydroxyl at the enzyme active site. Quaternary oximes, such as 2-hydroxyiminomethyl-1-methyl-pyridinium halide (2PAM), find clinical application as therapeutics against organophosphorus ester intoxication.<sup>15-18</sup> The pyridinium oximes (or more precisely, the conjugate base oximate anions) are nucleophiles that attack phosphorylated AChE to liberate active enzyme. Although these "reactivators" of inhibited enzyme constitute effective therapy, the pyridinium oximes as a class suffer from the disadvantage of limited tissue distribution. As charged species the pyridinium oximes penetrate poorly into hydrophobic cell membranes. Penetration of pyridinium oximes into the central nervous system is particularly poor and conventional therapy does little to counteract central effects of organophosphorus inhibitors.<sup>19-21</sup>

In an attempt to improve upon the limited activity of the pyridinium oximes we have undertaken an investigation of nonquaternary cholinesterase reactivators. Previously<sup>22,23</sup> we prepared a series of  $\alpha$ -ketothiohydroximates (1)




1


and evaluated them in vitro as reactivators of diisopropyl- and ethyl methyl-phosphonyl-AChE. Although the  $\alpha$ -ketothiohydroximates do reactivate phosphorylated-AChE, they are inferior in this regard to 2PAM. We attributed the lower reactivity of type 1 compounds, at least in part, to flexibility of the dialkylaminoalkyl side chain. We rationalized that the  $\alpha$ -ketothiohydroximates bind reversibly to the inhibited enzyme and that the reactivator/inhibited

enzyme complexes feature many configurations, only a small fraction of which have the oxime suitably positioned to react with phosphorylated serine at the active site.

In a continuation of our study of nonquaternary cholinesterase reactivators, we have prepared two new series of novel compounds. These are the heteroaromatic aldoximes, 2, and the 2-(diethylamino)ethyl  $\alpha$ -heteroaromatic thiohydroximates, 3:



**2**



**3**

JA-1043-139

where  $x = 0$  (for oxadiazoles),  $S$  (for thiadiazoles), or  $C_6H_5N$  (for 1-phenyl substituted triazoles); one ring nitrogen is in the 2-position and the second ring nitrogen is in the 3, 4, or 5 position;  $R = H, CH_3$  or  $C_6H_5$  in the 3, 4 or 5 substituent positions; and the hydroxyiminomethyl or diethylaminoethyl thiohydroximate functionalities are in the 4 or 5 positions.

We predicted that certain heteroaromatic systems would be sufficiently electronegative to lower the  $pK_a$ 's for the oxime/oximate acid base equilibria to approximately  $pK_a = 8$  (the empirically known optimal value for AChE reactivators).<sup>12</sup> We further considered that the heterocyclic rings would be approximately isosteric with the N-methyl pyridinium ring of 2PAM and that the compounds conforming to the general structure 2 would be appropriate nonquaternary analogs of the pyridinium aldoximes. However, we also anticipated that many examples of 2 would exhibit oxime acidities in the range  $pK_a = 9$  to 10 and that none of the heteroaromatic aldoximes would feature a cationic moiety (such as a quaternary pyridinium or protonated trialkyl amine functionality) to provide coulombic interaction with the aspartic acid carboxylate at the anionic region of the AChE active site.


Our previous work demonstrated that the protonated  $(C_2H_5)_2NCH_2CH_2S^-$  functionality contributes to reversible binding of nonquaternary reactivators to the AChE anionic region. Furthermore, for glyoxime,  $HC(:NOH)C(:NOH)H$ , and its analogous thioglyoximate,  $HC(:NOH)C(:NOH)SCH_2CH_2N(CH_3)_2$ , conversion of the aldoxime to the thiohydroximate ester lowers the oxime  $pK_a$  by nearly two units. Thus we wished to compare analogous type 2 and type 3 compounds with respect to oxime acidity, and reactivity toward inhibited AChE. We also hoped to further clarify the degree to which the flexible  $(C_2H_5)_2NCH_2CH_2S^-$  functionality influences the activity of nonquaternary oximes as reactivators of phosphorylated AChE.

In this report we describe the synthesis of seven examples of type 2 and type 3 compounds and their characterization with respect to structure and oxime acidity. We also detail preliminary findings on the activity of the compounds as reactivators of eel AChE inhibited by ethyl p-nitrophenyl methyl-phosphonate, EPMP.

## RESULTS AND DISCUSSION

### Synthesis and Structure

Table 1 gives structures and pertinent data for the series of heteroaromatic aldoximes 2a-2g. We synthesized the oxadiazole 2b, the triazole 2e, and the thiadiazoles 2f and 2g from the corresponding methyl derivatives using N-bromosuccinimide (NBS) as shown in reactions (1)-(4):



For the oxadiazole, 2a, we converted the methyl derivative directly to the oxime via nitrosation with alkyl nitrite in base, reaction (5)




Table 1  
SELECTED DATA FOR HETEROAROMATIC ALDOXINES

Code No.	Compd No.	$\chi$	$N_2^a$	$R_1$	$R_2$	$R_3$	$R_4/R_5$	Yield %	<sup>b</sup> NMR <sup>c</sup>		$pK_a^d$	Anal. e
									<sup>e</sup> C	<sup>f</sup> C		
4185-17	2a	0	4	f	f	C <sub>6</sub> H <sub>5</sub>	f/CINOH	30	161-163	12.87(hr)	7.88	C,H,N
4185-94	2b	0	5	f	f	CINOH	CH <sub>3</sub> /f	24	54-56	12.47(s)	9.15	C,H,N
4185-18	2c	N	3	C <sub>6</sub> H <sub>5</sub>	f	f	C <sub>6</sub> H <sub>5</sub> /CINOH	35	163-165	12.10(br)	9.25	C,H,N <sup>h</sup>
4185-19	2d	N	3	C <sub>6</sub> H <sub>5</sub>	f	f	CINOH/C <sub>6</sub> H <sub>5</sub>	70	194-196	11.47(s)	10.2	C,H,N
4185-85	2e	N	3	f	f	f	CINOH/f	29	241-243	12.17(s)	10.5	C,H,N
11879-10	2f	S	5	f	f	H	CINOH/f	16	148-149	12.10S(s)	9.45	C,H,N,S
11879-7	2g	S	5	f	f	CH <sub>3</sub>	CINOH/f	73	131-134	12.05(s)	9.61	C,H,N,S

<sup>a</sup>N<sub>2</sub>. Indicates ring position of second heterocyclic nitrogen atom.

<sup>b</sup>Based on conversion from starting aldehyde.

<sup>c</sup>In DMSO-d<sub>6</sub>.

<sup>d</sup>Determined spectrophotometrically in 0.1 M phosphate or glycine buffer.


<sup>e</sup>Experimental and calculated values for elements shown agree within  $\pm 0.4\%$  unless otherwise noted.

<sup>f</sup>No substituent.

<sup>g</sup>Peak area ratio = 20:80, respectively for 12.53:12.10 singlets.

<sup>h</sup>See experiment details section.


Reaction (5) appeared to be less generally useful than the synthesis route described above. Reaction (5) gave the desired product 2a in poor (30%) yield. Furthermore, substitution of a less hindered base (n-butyl lithium) for t-BuLi yielded the imine below as the only isolable product.



The major limitations to the sequence of reactions (1) through (4) are reluctance of some methyl-substituted heteroaromatics to undergo free-radical bromination and poor or incomplete oxidation of the alcohols to the aldehydes. Barring these limitations, the method does permit the rapid and versatile production of new oximes not readily accessible through alternative synthesis procedures. We found that 3-methyl-5-phenyl-1,2,4-oxadiazole was inert to bromination using NBS plus benzoyl peroxide in refluxing  $\text{CCl}_4$ . After 24 h, this reaction yielded only starting material. We succeeded in obtaining an approximate 10% yield of 3-bromomethyl-5-phenyl-1,2,4-oxadiazole only after reaction of the methyl compound with NBS, benzoyl peroxide, and  $\text{Br}_2$  using heat and light to initiate the reaction. Work is continuing on the preparation of this oxime.

Although we investigated numerous methods for oxidizing the hydroxy-methyl-substituted heteroaromatics to the corresponding aldehydes, only reaction (3), oxidation with ceric ammonium nitrate in water or 3 to 5 N  $\text{HNO}_3$ , generally provided the aldehydes cleanly and rapidly.

We prepared triazole aldoximes 2c and 2d via reactions (6) and (4):








Table 2 gives structures and pertinent data for  $\alpha$ -heteroaromatic thiohydroximates 3a through 3g. We prepared the thiohydroximates by treating the corresponding oximes with N-chlorosuccinimide (NCS) reaction (7), followed by esterifying the resulting hydroximoyl chlorides (4) with 2-(diethylamino)ethane thiol, reaction (8):




We determined pKa values for all type 2 compounds listed in Table 1, using a spectrophotometric technique.<sup>24</sup> We obtained pKa values for four of the  $\alpha$ -heteroaromatic thioglyoximates listed in Table 2, but were unable to determine accurate pKa's for the triazoles 3c-3e owing to poor aqueous solubility and small spectral changes as a function of pH for these three compounds.

We also recorded the hydroxyimino proton chemical shift for all examples of type 2 and for most examples of type 3 compounds. Thiohydroximates 3e and 3f (which were isolated as the amine free bases) did not show hydroxyimino proton signals. Similarly, the free base 3d exhibited a very broad signal for the hydroxyimino proton. For 3a, 3b and 3g (which we isolated as the amine hydrochloride salts) the hydroxyimino protons appeared as sharp singlets. This dependence of NMR chemical shift on the degree of protonation of the amine functionality suggests zwitterion formation in DMSO solution for thiohydroximates added in the free base form, i.e., reaction (9)

Table 2  
SELECTED DATA FOR  $\alpha$ -HETEROAROMATIC THIONYDROXIMATES

Code No.	Cmpd. No.	$\chi$	$N_2^a$	$R_1$	$R_2$	$R_3$	$R_4^b$	$R_5^b$	Yield <sup>c</sup> %	m.p. °C	$^{13}\text{NMR}$ (-NOH) $\delta$	$pK_a^e$	Analysis
4185-54	3a	0	4	S	S	$C_6H_5$	S	$C(\text{NOH})SR_6$	27	199-201	13.88(s)	6.32	$C, H, N$
4185-96	3b	0	5	S	S	$C(\text{NOH})SR_6$	$CH_3$	S	41	121-122	13.14(s)	7.59	$C, H, N, S, Cl$
50	4185-43	N	3	$C_6H_5$	S	S	$C_6H_5$	$C(\text{NOH})SR_7$	24	152-155	12.58(br)	h	$C, H, N, S$
	4185-41	N	3	$C_6H_5$	S	S	$C(\text{NOH})SR_7$	$C_6H_5$	83	185-187	12.13(s)	h	$C, H, N, S$
4185-88	3e	N	3	$C_6H_5$	S	S	$C(\text{NOH})SR_7$	H	44	241-243	h	h	$C, H, N, S, I$
11879-14	3f	S	5	S	S	H		$C(\text{NOH})SR_7$	8	122-124	h	7.69	$C, H, N, S^f$
11879-12	3g	S	5	S	S	$CH_3$		$C(\text{NOH})SR_6$	39	179-182	12.72(s)	8.65 <sup>g</sup>	$C, H, N, S, Cl$



<sup>a</sup>  $N_2$  indicates ring position of second heterocyclic nitrogen atom.

<sup>b</sup>  $R_6 = CH_2CH_2N(C_2H_5)_2\text{HCl}$  and  $R_7 = CH_2CH_2N(C_2H_5)_2$ .

<sup>c</sup> Based on conversion from starting heteroaromatic hydroximoyl chloride.

<sup>d</sup> In  $DMSO-d_6$ .

<sup>e</sup> Determined spectrophotometrically in 0.1 M phosphate or glycine buffer.


<sup>f</sup> Experimental and calculated values for elements shown agree within  $\pm 0.4\%$  unless otherwise noted.

<sup>g</sup> No substituent.

<sup>h</sup> Not determined.


<sup>i</sup> See experimental details section.

<sup>j</sup> Determined potentiometrically in 0.1 M  $\text{NaCl}(4)$ .




Compound 3c appeared to be anomalous in this regard, the free base form showing a sharp oxime proton signal. The two phenyl substituents that flank the hydroxyimino functionality perhaps limited the ionization shown in reaction (9).

Of the seven heteroaromatic aldoximes shown in Table 1 only one (2f) exhibited two sets of proton signals, indicating a mixture of E- and Z-aldoxime isomers. The major component (80%) of the mixture exhibited proton resonances at  $\delta$  12.10 (=NO-H), 9.12 (=C-H), and 8.43 (Ar-H), whereas the minor isomer showed peaks at  $\delta$  12.53 (=N-OH), 9.50 (C-H), and 7.95 (Ar-H). For a wide variety of aldoximes, the isomers with hydroxyimino hydroxyl group cis to the trigonal carbon hydrogen exhibit methine proton resonances that are shifted upfield, and ortho-aromatic ring protons that are shifted down-field, from the comparable resonances exhibited by the isomer with hydroxyl group trans to the aldehydic =C-H.<sup>26-29</sup> By analogy, we assign the Z- and E-configurations respectively to the major and minor components of the 2f isomer mixture.



Z-2f  
(Major Component)



E-2f  
(Minor Component)


JA-1043-138

Aldoximes with cis-hydroxyl and aldehydic =C-H groups typically exhibit hydroxyimino proton chemical shifts at higher field than the trans isomers.<sup>26-</sup><sup>27</sup> The hydroxyimino resonances for Z- and E-isomers of 2f occurred at high and low field, respectively, opposite to the trend expected by analogy with reported compounds. We consider that the assignment of Z- and E-configurations as shown above for 2f are valid on the basis of NMR data for the methine


and ring protons. The anomalous chemical shift observed for the hydroxyimino proton in Z-2f could be a result of intramolecular hydrogen bonding to the ring nitrogen.

We hoped to establish configurations for the other examples of type 2 compounds in Table 1, but such assignments are treacherous in the absence of pairs of E- and Z-isomers or crystallographic data.<sup>28-31</sup> Therefore, at present we do not assign isomeric configurations for heteroaromatic aldoximes other than 2f.

We also wished to determine configurations for the  $\alpha$ -heteroaromatic thiohydroximates in Table 2. For the related  $\alpha$ -ketothiohydroximates, type 1 compounds we previously<sup>22</sup> suggested an E-configuration favored by intramolecular hydrogen bonding although IR spectral data supported a Z-configuration for 2-(diethylamino)ethyl p-bromophenylthiohydroximate, 5.




E-Aryltiethoximate




5  
Z-Aryltiethoximate

JA-1043-136


We also previously found a linear correlation between hydroxyimino proton chemical shift and acidity for type 1 compounds. To compare the  $\alpha$ -heteroaromatic-aldoximes and -thiohydroximates with related compounds, we plotted  $=\text{NO}-\text{H}$  proton chemical shift versus oxime pKa for 1, 2, 3, 5 and 2PAM. In this plot we also included literature data<sup>25</sup> for thiadiazolyl aldoximes 6a-6c



6a



6b



6c

JA-1043-137


Figure 1 shows two general linear correlations: one for  $\alpha$ -keto and  $\alpha$ -heteroaromatic thiohydroximates (the dashed line); and a second correlation (solid line) for 2PAM, 5, 6, and most type 2 compounds. Least-squares linear regression of the data for type 1 and type 3 compounds gave equation (10):

$$pK_a = (26.2 \pm 1.3) - (1.43 \pm 0.12)\delta \quad (10)$$

and similar treatment of the data for 5, 6, 2PAM, and type 2 compounds (excluding 2a and 2c) gave equation (11):

$$pK_a = (25.2 \pm 1.1) - (1.30 \pm 0.091)\delta \quad (11)$$


The above correlations were rather imprecise, and the differences between the two general classes of compounds were small but apparently real. We tentatively conclude that the differences relate to the availability (or lack thereof) of intramolecular hydrogen bonding for hydroxyimino protons. Thus data for 3a, 3b and 3g best fit the correlation for type 1 compounds. Because 1 exhibit intramolecular hydrogen bonding, we suggest an E-configuration for the  $\alpha$ -heteroaromatic thiohydroximates.




E-3

JA-1043-135

Interestingly, the  $pK_a$  and NMR data for 2a (the parent compound of 3a) correlated better with equation (10) (the dashed line in Figure 1) than with equation (11). One possible explanation is a Z-configuration for 2a with hydrogen-bonding to the ring nitrogen.



Z-2a




JA-1043-21

**FIGURE 1** Oxime proton NMR chemical shift versus  $pK_a$  for:  
 $\alpha$ -ketothiohydroximates, 1, □—□ (data of references 22, 23);  
 $\alpha$ -heteroaromatic thiohydroximates, 3, ◇—◇ (data of Table 2);  
 $\alpha$ -heteroaromatic aldoximes, 2, ▲—▲ (data of Table 1);  
 $\alpha$ -thiadiazoyl aldoximes, 6, △—△ (data of reference 25);  
 2-hydroxyiminomethyl-1-methylpyridinium iodide, 2PAM, O; and  
 $4\text{-BrC}_6\text{H}_4\text{Cl}(:\text{NOH})\text{SCH}_2\text{CH}_2\text{N}(\text{C}_2\text{H}_5)_2$ , 5, ⊙ (Data of reference 22).

We emphasize that in the absence of further data our assignments for configurations of 2a and 3a, 3b and 3e are tentative. Nevertheless, the proposed structural relationships are plausible, consistent with the observed data, and illustrative of the types of bonding interactions that can be generally important for hydroxyimino compounds.

To summarize, we find the triazolyl aldoximes, as a class, to be poorly soluble in water and very weak acids. The related triazolyl thiohydroximates were also poorly soluble and this appears to be a major limitation of the triazolyl compounds. Of all the compounds in Table 1 only 2a exhibited an acidity ( $pK_a = 7.88$ ) near the optimal value for reactivators. Interestingly, of the three thiadiazolyl aldoximes reported by Benschop et al.,<sup>25</sup> 6c was the most acidic ( $pK_a = 6.97$ ). This suggests that the general heteroaromatic structure



with a 1,2,4-ring substitution pattern is particularly electron-withdrawing. We are currently uncertain whether inductive and/or resonance effects primarily contribute to the electron-withdrawing properties of these compounds. In either case, it appears that as a class 5-hydroxyiminomethyl 1,2,4-trisubstituted heteroaromatics would feature oxime  $pK_a$ 's in a useful range.

Converting various type 2 compounds to type 3 compounds did lower hydroxyimino proton  $pK_a$ 's by 1.5 to 2 units. This compares favorably with the difference in  $pK_a$  values (9.9 versus 8.4, respectively) previously<sup>23</sup> observed for glyoxime and 2-(diethylamino)ethyl thioglyoximate. The effect on  $pK_a$  of substituting an aminoalkyl thioester for an aldehydic hydrogen has practical significance because the substitution in some cases converts hydroxyimino compounds (e.g., aldoximes) with otherwise low acidity to analogs (thiohydroximates) that dissociate appreciably to the reactive oximate anion at physiological pH. The degree to which such substitution actually influences the activity of  $\alpha$ -heteroaromatic hydroxyimino compounds as reactivators of phosphylated AChE is discussed in the following section.

#### Acetylcholinesterase Reactivation

##### Screening for Activity

We screened type 2 and type 3 compounds for in vitro activity as reactivators of ethyl methylphosphonyl-AChE. The method involved incubating ethyl *p*-nitrophenyl methylphosphonate with a slight excess of eel AChE followed by

incubating of the inhibited enzyme at pH 7.6 and 25°C with various concentrations of test compounds and assaying for restored enzymatic activity. The general method has been described in detail.<sup>23</sup>

For the determining of reactivation data we defined the percentage reactivation after t min incubation according to equation (12)

$$\%R_t = 100 \frac{(A_t - AI_t)}{(A_c - AI_t)} \quad (12)$$

where  $A_t$  is activity of reactivated AChE at time t,  $AI_t$  is activity (at time t) of AChE inhibited with EPMP, and  $A_c$  is control AChE activity (= activity of uninhibited enzyme or = mean value of uninhibited enzyme activity and enzyme activity after complete reactivation with 2PAM). All activities reported herein are net activities corrected for spontaneous and reactuator-induced hydrolysis of substrate in assay solutions. The data that follow are not corrected for inhibition of AChE by test compounds.

In comparing various reactivators we have calculated reactuator concentrations on the dual basis of the concentration of the protonated hydroxyimino form (HOX) of added test compound and on the concentration of the anionic oximate form (OX), where

$$[OX] = [HOX] \{1 + \text{antilog}[pK_a - 7.6]\}^{-1} \quad (13)$$

Table 3 shows the percent restoration of AChE activity after incubating the inhibited enzyme with reactivators for 120 and 240 min.

The table shows pronounced differences in activity for various examples of 2 and 3. Compounds 2c and 3e were insoluble in water or in 10% EtOH, even at low concentrations, and we were unable to obtain reactivation data for these materials. Compounds 2d, 2e, 3c and 3d were sparingly soluble in water but dissolved in 10% EtOH at the indicated concentrations. Reactivation data for 2d, 2e, 3c and 3d were obtained in aqueous ethanol using appropriate control solutions. All other data were obtained in water.

The  $\alpha$ -heteroaromatic aldoximes 2d, 2e, 2f, and 2g showed no significant activity as reactivators at the concentrations tested. We attribute this lack of activity to the low acidities of the aldoximes and the correspondingly low concentrations of the nucleophilic oximate species at pH 7.6.

Two of the aldoximes, 2a and 2b, did reactivate ethyl methylphosphonyl-AChE: indeed 2a was the most active of any of the compounds investigated to date.

All of the  $\alpha$ -heteroaromatic thiohydroximates (except 3c) reactivated phosphorylated-AChE significantly. As a class, the  $\alpha$ -triazolyl thiohydroximates (3c, 3d, and 3e) reactivated poorly. In general, the aldoxime and

Table 3

PERCENT REACTIVATION ( $ZR_t$ ) OF ETHYL METHYLPHOSPHONYL-AChE  
AFTER INCUBATION WITH REACTIVATORS AT VARIOUS  
CONCENTRATIONS AT 25°C, pH 7.6

Compound <sup>a</sup> No.	[HOX] <sup>b</sup> mM	[OX] <sup>c</sup> mM	$ZR_t$ <sup>d</sup> After Incubation for $t$ , min	
			$t=120$	$t=240$
2a	0.500	0.172	100	98
	0.200	0.0688	78	90
2b	1.00	0.0274	7.0	12
	0.100	0.00274	1.0	3.0
2c	0.100	0.00219	e	e
2d	0.0500	0.00013	f	f
	0.0250	0.00007	f	f
2e	1.00	0.00126	3.5	f
	0.100	0.00013	f	f
2f	1.00	0.0139	f	f
2g	1.00	0.00968	f	f
3a	1.00	0.950	6.0	8.9
	0.100	0.0950	11	21
3b	0.500	0.500	19	34
	0.100	0.0500	11	15
3c	0.100	g	f	1.7
3d	0.100	g	2.8	5.7
3e	0.100	g	e	e
3f	1.00	0.448	47	59
	0.500	0.224	29	37
3g	1.00	g	28	42
	0.500	g	7.7	17
2PAM	0.0100	0.00289	93	97

<sup>a</sup>See Tables 1 and 2 for structures.

<sup>b</sup>[HOX] is the concentration of added test compound.

<sup>c</sup>[OX] is the concentration of anionic form of added test compounds, calculated according to equation (13).

<sup>d</sup> $ZR_t$  calculated according to equation (12).

<sup>e</sup>Compound was insoluble at indicated concentration. Reactivation data not obtained.

<sup>f</sup>Reactivation not detectable, < 1%.

<sup>g</sup>No pKa available for compound [OX] not calculated.

thiohydroximate derivatives of triazoles appear to be poor candidates for nonquaternary reactivators.

The  $\alpha$ -oxadiazolyl thiohydroximates 3a and 3b were modest reactivators of ethyl methyl phosphonyl-AChE. Thiohydroximate 3a was substantially less reactive toward phosphonylated AChE than the corresponding aldoxime 2a, which we attribute at least in part to high acidity ( $pK_a = 6.32$ ) of the thiohydroximate and low nucleophilicity of the conjugate base oximate form of 3a. Compound 3a was not well-behaved in our in vitro assay; higher concentrations of 3a actually reactivated inhibited enzyme more slowly and less completely than low concentrations. This suggests inhibition of AChE by 3a itself at high concentration.

The thiohydroximates 3b, 3f and 3g were more reactive towards phosphonyl AChE than the corresponding aldoximes 2b, 2f and 2g, presumably a result of  $pK_a$  differences.

None of the type 3 compounds tested surpassed 2a as a reactivator of ethyl methylphosphonyl-AChE and 2a was significantly less reactive than 2PAM toward the inhibited enzyme.

#### Reactivation Kinetics

To more accurately assess structure-activity relationships among the nonquaternary AChE reactivators, it is necessary to examine reactivation kinetics. The reactivation of ethyl methylphosphonyl-AChE proceeds via the mechanism shown in equation (14):



where OX is the oximate form of the reactivator, EOP is phosphonylated enzyme,  $[OX \cdot EOP]$  is a reversibly formed reactuator/inhibited enzyme complex, and EOH is active enzyme.

Under conditions where reactuator is present in large excess over inhibited enzyme, we have shown<sup>22,23</sup> that the following equations can be obtained:

$$\ln(100 - ZR_t) = k_{obs} \cdot t \quad (15)$$

$$(k_{obs})^{-1} = \frac{K_r}{k_r} [OX]^{-1} + \frac{1}{k_r} \quad (16)$$

$$k_b = k_r / K_r \quad (17)$$

$$k_{eff} = k_b [1 + \text{antilog } (pK_a - 7.6)]^{-1} \quad (18)$$

where  $k_{obs}$  is a pseudo-first-order observed rate constant for reactivation,  $K_r$  is the equilibrium constant for dissociation of the reactuator/inhibited enzyme complex,  $k_r$  is the rate constant for displacement of inhibitor from the reactuator/inhibited enzyme complex,  $k_b$  is equivalent to a bimolecular rate constant for reactivation in the limit of low reactuator concentration, and  $k_{eff}$  is an effective rate constant for reactivation that accounts for the fraction of added test compound present as the oximate form at pH = 7.6.

To date we have determined reactivation kinetics at four different oximate concentrations only for 2a. We have determined reactivation kinetics at one or two oximate concentrations for 2b, 3a, 3b, 3f and 3g. Because equation (16) requires a minimum of three different points for valid calculation of  $K_r$  and  $k_r$  values, and because we wished to make at least preliminary comparisons of reactuator activity, we calculated apparent bimolecular rate constants ( $k_{app}$ ) for reactivation of phosphonylated AChE by oximate anion according to equation (19):

$$k_{app} = k_{obs} \cdot [OX]^{-1} \quad (19)$$

Because equation (19) is only an approximation,  $k_{app}$  values determined at high reactuator concentration underpredict inherent oximate reactivity. Furthermore, in our calculations we have not corrected for AChE inhibition by reactiators themselves, and at least for 3a, inhibition was apparently significant. With these caveats in mind, we can examine the calculated  $k_{app}$  values and use them as a first approximation to rate relative activities for the various reactiators. Table 4 gives  $k_{app}$  values calculated as above for six different reactiators.

The table demonstrates the remarkable differences in activity for the reactiators. Both oxadiazolyl aldoximes 2a and 2b exhibited  $k_{app}$  values higher than any of the related thiohydroximates. It is especially interesting that, 2a was more reactive than the analogous 3a by approximately two orders of magnitude. We had anticipated that converting the aldoxime to the thiohydroximate form would enhance affinity of reactiator for the anionic region of the enzyme active center and therefore enhance reactivity towards ethyl methylphosphonyl-AChE. Such is not the case, however. We attribute the relatively low activity of 3a, in part, to high oxime acidity (low oximate nucleophilicity) and perhaps also to inhibition of AChE by reactiator.

The relatively low activity of the  $\alpha$ -heteroaromatic thiohydroximates as a class seems significant. Poor oximate nucleophilicity seems an unlikely explanation for low activity of 3b, 3f and 3g insofar as all three compounds exhibited pKa values near pKa = 8. We previously demonstrated<sup>22,23</sup> that the 2-(diethylamino)ethyl functionality in 3 significantly contributes toward reversible binding of the reactiator to inhibited-AChE; thus low affinity of oximate for the anionic region of AChE cannot readily explain the observed lower activities.

Table 4

APPARENT BIMOLECULAR RATE CONSTANTS ( $k_{app}$ ) FOR REACTIVATION  
OF ETHYL METHYLPHOSPHONYL-AChE AT 25°C, pH 7.6

Compounds <sup>a</sup> No.	[HOX] <sup>b</sup> mM	[OX] <sup>c</sup> mM	$k_{obs}^d$ $\text{min}^{-1} \times 10^3$	$k_{app}^e$ $\text{M-min}^{-1}$
<u>2a</u>	0.200	0.0688	36.3 ± 0.17	528
	0.0300	0.0103	5.58 ± 0.29	542
<u>2b</u>	1.00	0.0274	0.375 ± 0.026	13.7
	0.100	0.00274	0.054 ± 0.026	19.7
<u>3a</u>	1.00	0.950	0.834 ± 0.059	0.878
	0.100	0.0950	0.393 ± 0.021	4.14
<u>3f</u>	1.00	0.448	2.44 ± 0.28	2.60
	0.500	0.224	1.67 ± 0.12	7.46
<u>3g</u>	1.00	0.334	2.34 ± 0.12	7.01
	0.100	0.0334	0.758 ± 0.033	22.7

<sup>a</sup>See Tables 1 and 2 for structures.

<sup>b</sup>[HOX] is concentration of added test compound.

<sup>c</sup>[OX] is concentration of oximate form of reactivator, calculated according to equation (13).

<sup>d</sup>Calculated according to equation (15), error limits are linear-least squares standard deviations.

<sup>e</sup>Calculated according to equation (19).

To better understand the factors that control activity of the reactivators it is helpful to examine reactivation rate constants determined as in equations (15) through (18). Table 5 summarizes these data for 2a, and for comparison gives earlier data<sup>23</sup> for 2PAM, and  $\text{BrC}_6\text{H}_4\text{C}(\text{O})\text{C}(\text{NOH})-\text{SCH}_2\text{CH}_2\text{N}(\text{C}_2\text{H}_5)_2 \cdot \text{HCl}$ , 1a (code SR 3018). The table shows that, in terms of  $k_b$  values, 2a was more reactive than 1a toward ethyl methylphosphonyl-AChE by a factor of approximately six and less reactive than 2PAM by a factor of approximately 20. Surprisingly, 2a and 1a exhibited nearly equivalent values for  $K_r$ , despite the fact that 1a bears a cationic moiety (protonated diethylaminoethyl group) whereas 2a does not (the ring nitrogens of heteroaromatics such as pyridine are poorly protonated at pH 7.6 and the same should be true for the oxadiazole 2a).

We previously suggested<sup>23</sup> that  $k_r$  and  $K_r$  values cannot be independently interpreted and that  $K_r$  does not necessarily reflect the fraction of reactuator bound to inhibited AChE. Rather  $K_r$  relates to the fraction of bound oximate that actually displaces inhibitor from the reactuator/inhibited enzyme complex. We postulated that the dialkylaminoalkyl thiohydroximic acid S-esters, which exhibit many rotational degrees of freedom, bind to inhibited AChE with multiple low-energy conformations and that only a relatively small fraction of the conformations of the oximate/inhibited enzyme complex have a geometry that favors attack by oximate oxygen on phosphorus. We rationalized the powerful reactivity of 2PAM on the basis of strong affinity for inhibited AChE plus a relatively small number of total low energy conformations and a high proportion of available conformations with geometry suitable for reactivation.

In this context 2a seems to afford relatively high activity toward ethyl methylphosphonyl-AChE, at least in part because the molecule is relatively rigid and resembles 2PAM in the number of low energy conformations. The available data do not directly address the relative binding affinities of 2a and 2PAM for inhibited AChE. Because 2a has no cationic functionality to provide electrostatic attraction for the AChE anionic region, hydrophobic forces presumably govern the reversible binding of the reactuator to the inhibited enzyme.

The data of Table 4 show that the aldoximes 2a and 2b were more reactive than the corresponding  $\alpha$ -heterocyclic thiohydroximic acid esters. Even for compounds that exhibited similar pKa values and reasonably isosteric heterocycles, incorporation of the 2-(diethylamino ethyl) moiety into the general molecular framework lowered activity towards inhibited enzyme. Because obvious chemical differences in nucleophilicity or steric bulk are not apparent, we consider that the difference in reactivity between  $\alpha$ -heteroaromatic aldoximes and thiohydroximates relate to entropic factors and differences in rigidity for the two types of compounds.

#### Conclusions and Future Work

Nonquaternary reactivators based on heteroaromatic aldoximes seem likely candidates for treatment of central nervous system effects of organophosphorus

Table 5

KINETIC PARAMETERS FOR REACTIVATION OF ETHYL  
METHYLPHOSPHONYL-ACHE AT 50°C, pH 7.6

Compd <sup>a</sup> No.	[NOX] <sup>b</sup> M	[OX] <sup>c</sup> M <sup>-1</sup> x 10 <sup>-3</sup>	k <sub>obs</sub> <sup>d</sup> min <sup>-1</sup> x 10 <sup>3</sup>	(k <sub>obs</sub> ) <sup>-1</sup> min	Slope <sup>e</sup> M-min x 10 <sup>2</sup>	Intercept <sup>e</sup> min	k <sub>r</sub> <sup>e</sup> min <sup>-1</sup> x 10 <sup>3</sup>	k <sub>r</sub> <sup>f</sup> M x 10 <sup>4</sup>	k <sub>b</sub> <sup>f</sup> M-min <sup>-1</sup>	k <sub>eff</sub> <sup>g</sup> M-min <sup>-1</sup>
2a	0.500	5.99	45.0 ± 5.3	22.2	0.171 ± 0.0099	9.43 ± 5.3	106	1.81	585	195
	0.200	15.0	36.3 ± 0.17	27.6						
	0.0800	37.4	12.4 ± 0.52	80.1						
	0.0300	99.8	5.58 ± 0.79	179						
1a	h	h	h	h	1.05 ± 0.144	41.5 ± 35	24.1	2.53	95.3	56.3
2PAM	h	h	h	h	0.0104 ± 0.00064	27.8 ± 24	36.0	0.0374	9630	2780

<sup>a</sup>See Table 1 for structure. 1a is BrC<sub>6</sub>H<sub>4</sub>C(=O)(NOH)SCH<sub>2</sub>CH<sub>2</sub>N(C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>•HCl.<sup>b</sup>[NOX] is concentration of added test compound.<sup>c</sup>[NOX] is concentration of oximate form of added test compound calculated according to equation (13).<sup>d</sup>Calculated according to equation (15).<sup>e</sup>Calculated according to equation (16).<sup>f</sup>Calculated according to equation (17).<sup>g</sup>Calculated according to equation (18).<sup>h</sup>See reference 23 for original data.

ester poisoning. Benschop et al<sup>25</sup> found thiadiazole 6a to be less reactive than 2PAM toward phosphorylated-AChE but nevertheless observed useful therapeutic activity for the nonquaternary aldoxime. We showed that the  $\alpha$ -keto-thiohydroximate 1a was one-fiftieth as potent as 2PAM in vitro as a reactivator of ethyl methylphosphonyl-AChE, but equivalent to 2PAM as a reactivator of mouse diaphragm AChE, and superior to 2PAM as reactivator of brain AChE in vivo. Oxadiazole 2a is more reactive toward phosphorylated-AChE than 1a by a factor of approximately three. This raises the possibility that 2a may also be more effective than 1a at reversing the toxic effects of organophosphorus inhibitors in vivo. This possibility should be evaluated in future work.

As a class,  $\alpha$ -heteroaromatic aldoximes appear to be more reactive in vitro than analogous  $\alpha$ -heteroaromatic thiohydroximates toward ethyl methyl-phosphonyl-AChE. We interpret this behavior in terms of the structural flexibility that is available to dialkylaminoalkyl thiohydroximic acid esters that contributes to a reduction in the entropy of activation for the reactivation of inhibited AChE. This hypothesis must be fully evaluated and we plan to determine reactivation kinetics for compounds such as 3a and 3g to more clearly elucidate the controlling factors.

The 5-hydroxyiminomethyl-1,2,4-oxadiazole or -1,2,4-thiadiazole structure appears to be a useful framework for developing improved reactivators. Compound 2a is the most powerful nonquaternary reactivator that we have examined so far. 2a is approximately one-fifteenth as reactive toward phosphorylated-AChE as 2PAM. In general, the nonquaternary reactivators exhibit strong dependence of activity on structure. We will prepare substituted analogs of 2a in an effort to obtain  $\alpha$ -heterocyclic aldoximes with inherent activity comparable with that of 2PAM.

## EXPERIMENTAL DETAILS

### Materials

Melting points were obtained in glass capillaries with a Laboratory Devices Mel-Temp apparatus and are presented uncorrected. Infrared spectra were determined with Perkin-Elmer Models 281 and 735B spectrophotometers. Nuclear magnetic resonance spectra were obtained with a Varian Associates EM-360 spectrometer, and chemical shifts are reported in parts per million ( $\delta$ ) relative to an internal tetramethylsilane reference. C,H,N, microanalysis was performed with a Perkin-Elmer 240 elemental analyser. Other elements were analyzed at Stanford University analytical laboratory. Elemental analytical results are reported below only for compounds whose observed values were not within  $\pm 0.4\%$  of theoretical.

The following heterocyclics were prepared according to literature methods: 3-phenyl-5-methyl-1,2,4-oxadiazole (7a);<sup>32</sup> 3,4-dimethyl-1,2,5-oxadiazole (7b);<sup>33</sup> 3-methyl-5-phenyl-1,2,4-oxadiazole (7c);<sup>34</sup> 1,4-diphenyl-5-formyl-1,2,3-triazole (7d);<sup>35</sup> 1,5-diphenyl-4-formyl-1,2,3-triazole (7e);<sup>35</sup> 1-phenyl-4-formyl-1,2,3-triazole (7f);<sup>36</sup> 3-methyl-1,2,5-thiadiazole (7g);<sup>37</sup> and 3,4-dimethyl-1,2,5-thiadiazole (7h).<sup>22,23</sup> Other materials were prepared or obtained as previously described.<sup>22,23</sup>

### 3-Phenyl-5-hydroxyiminomethyl-1,2,4-oxadiazole (2a)

Oxadiazole 7a (1.6 g, 0.01 mol) was dissolved in 40 mL of freshly distilled tetrahydrofuran and cooled to -78°C. To this solution, t-butyl-lithium (2.0 M, in 6 mL pentane, 0.012 mol) was added slowly. Subsequently addition of 1-C<sub>2</sub>H<sub>5</sub>ONO (1.1 g, 0.012 mol) followed by acidification of the solution with 30 mL of 4N HCl, extraction with three 20-mL portions of ether, drying the combined ether extracts over MgSO<sub>4</sub>, and removal of solvent, yielded 1.2 g of 2a contaminated with starting material 7a. Sublimation of the crude product gave 0.150 g (5.0%) of 2a, m.p. 161-163°C. NMR (DMSO-d<sub>6</sub>),  $\delta$  12.87 (br, s, 1H, N-OH); 8.37 (s, 1H, CHNOH); 8.00 (m, 2H, phenylaromatic) and 7.56 ppm (m, 3H, phenylaromatic). IR (KBr) 3225 (s), 2960 (m), 1540 (m), 1430 (s), 1345 (s), 1035 (s) and 990 (s) cm<sup>-1</sup>. Analysis: C,H,N.

### 3-Phenyl-1,2,4-oxadiazol-5-yl hydroximoyl chloride (4a)

Compound 2a (0.94 g, 5.0 mmol) dissolved in 30 mL dimethylformamide was treated with 0.67 g (5.0 mmol) of N-chlorosuccinimide. The resulting mixture was stirred 15 min followed by bubbling approximately 15 mL of HCl (g) through the solution. The solution was stirred an additional 15 min, and then was heated to 55°C and allowed to cool slowly (approximately 1 h). The resulting mixture was poured into 200 mL water and extracted with two 100-mL portions of ether. The ether extracts were combined, washed with three 100-mL portions water, dried over anhydrous MgSO<sub>4</sub>, filtered, and solvent evaporated yielding

0.94 g (85%) of a white amorphous solid; m.p. 155-159°C. The crude reaction product was assigned the hydroximoyl chloride structure of 4a, based on the following: NMR (DMK-d<sub>6</sub>) δ 12.70 (s, 1H, NOH), 8.15 (m, 2H, phenyl), and 7.57 ppm (m, 3H, phenyl). Analysis for C<sub>9</sub>H<sub>6</sub>N<sub>3</sub>O<sub>2</sub>Cl; Cal'd: C, 48.32; H, 2.68; N, 18.79. Found: C, 51.03; H, 2.93; N, 18.24.

3-Phenyl-1,2,4-oxadiazol-5-ylthiohydroximic acid 2-(Diethylamino)ethyl S-Ester Hydrochloride (3a).

To the crude hydroximoyl chloride 4a (0.90 g, 4.0 mmol) was added 0.68 g (4.0 mmol) of diethylaminoethanethiol hydrochloride dissolved in 75 mL chloroform which contained 2 mL of freshly distilled triethylamine. The total reaction volume was increased to 100 mL by adding an additional 25 mL chloroform and the resulting solution was stirred overnight. The reaction mixture was subsequently washed with two 100 mL portions of water, dried over anhydrous MgSO<sub>4</sub>, filtered, and the solvent removed on the rotary evaporator yielding 1.21 g of crude 3a. The crude material was purified by column chromatography using 100% diethyl ether eluant. The crude product was dissolved in a minimal amount of ether and placed on a silica-gel column. Fractions of 40 mL were collected and examined by TLC, like fractions were combined and concentrated yielding 0.35 g (27%) of an analytically pure yellow oil. Analysis: C, H, N.

Purified 3a was converted to its HCl salt by dissolving the chromatographed product in diethyl ether followed by the dropwise addition of an ethereal solution saturated with HCl gas. White crystals of the hydrochloride precipitated from solution and were filtered and dried in vacuum, m.p. 199-201°C (Dec). NMR (DMSO-d<sub>6</sub>), δ 13.88 (br, s, 1H, NOH), 8.10 (m, 2H, phenyl), 7.69 (m, 3H, phenyl), 3.63 (m, 2H, SCH<sub>2</sub>), 3.17 (m, 6H, CH<sub>2</sub>), and 1.17 ppm (t, 6H, CH<sub>3</sub>).

3-Bromomethyl-4-methyl-1,2,5-oxadiazole\*

In a 500-mL round bottom flask was placed 24.5 g (0.25 mole) of freshly distilled 3,4-dimethyl-1,2,5-oxadiazole (7b), 44.5 g (0.25 mole) of N-bromo-succinimide, 1.5 g of benzoyl peroxide, and 600 mL of carbon tetrachloride. The resulting slurry was refluxed overnight, filtered hot into 1 L of water and the organic layer subsequently washed with three 250-mL portions of water. The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated, yielding 33.5 g of crude product. The NMR of the crude material showed an approximate 60% conversion with the remainder starting material. The mono-bromide can be distilled at 96-100°C under a water aspirator vacuum; however, the crude material was used in subsequent reactions without further purification; NMR (CDCl<sub>3</sub>), δ 4.59 (s, 2H, CH<sub>2</sub>Br) and 2.50 ppm (s, 3H, CH<sub>3</sub>).

---

\*Caution: 3-Bromomethyl-4-methyl-1,2,5-oxadiazole is a severe lacrymator and should be handled accordingly.

### 3-Hydroxymethyl-4-methyl-1,2,5-oxadiazole

In a 500-mL round bottom flask was placed 33.5 g of the crude 3-bromo-methyl-4-methyl-1,2,5-oxadiazole, prepared as above, 25 g of potassium carbonate and 350 mL of water. The resulting mixture was heated to 90°C and stirred for 90 minutes. The resulting aqueous solution was decanted from a small amount of residual oil, saturated with sodium chloride, and extracted with three 75-mL portions of diethyl ether. The combined ether extracts were dried over  $MgSO_4$ , filtered and concentrated, yielding 11.95 g of the crude alcohol. The NMR of the crude alcohol showed a 30% contamination with 3,4-dimethyl-1,2,5-oxadiazole. The 3-hydroxymethyl compound was used without further purification. NMR ( $CDCl_3$ ),  $\delta$  4.88 (s, 2H,  $CH_2$ ), 4.55 (br, s, 1H, OH) and 2.47 ppm (s, 3H,  $CH_3$ ).

### 3-Formyl-4-methyl-1,2,5-oxadiazole

To 100-mL of 3.5 N nitric acid was added 11 g of the crude 3-hydroxy-methyl-4-methyl-1,2,5-oxadiazole prepared above. To this solution, preheated to 50°C, was added 132 g of ceric ammonium nitrate in 300 mL of 3.5 N nitric acid, and the resulting mixture stirred at this temperature for 6 hr. The resulting mixture was cooled, extracted with three 75-mL portions of methylene chloride, the combined extracts washed with two 100-mL portions of water, then with 100 mL of 1 N  $NaHCO_3$  and 100 mL brine. The methylene chloride was dried over anhydrous  $MgSO_4$ , filtered and solvent evaporated, yielding 5.0 g of crude aldehyde. The NMR of the crude product indicated the presence of three components; methylene chloride, aldehyde and starting material 3,4-dimethyl-1,2,5-oxadiazole. An overall yield of 3.75% from the dimethyl compound, 7b was recorded. NMR ( $CDCl_3$ ),  $\delta$  10.40 (s, 1H, C(O)H) and 2.62 ppm (s, 3H,  $CH_3$ ).

### 3-Hydroxyiminomethyl-4-methyl-1,2,5-oxadiazole (2b)

3-Formyl-4-methyl-1,2,5-oxadiazole (1.12 g, 10 mmol) dissolved in 100 mL of absolute ethanol was treated with 0.7 g (10 mmol) of hydroxylamine hydrochloride and 0.79 g (10 mmol) of pyridine. The resulting mixture was refluxed for two hr. The ethanol was removed under aspirator vacuum and the residue taken up in 100 mL diethyl ether. The ethereal solution was washed with two 50-mL portions of 1 N HCl, dried over anhydrous  $MgSO_4$ , filtered and concentrated, yielding 750 mg of a white amorphous solid which proved to be a mixture of the desired oxime contaminated with 3,4-dimethyl-1,2,5-oxadiazole. Recrystallization from 30-60°C petroleum ether yielded 300 mg (23.6%) of analytically pure 2b; m.p. 54-56°C. NMR ( $DMSO-d_6$ ),  $\delta$  12.42 (s, 1H, NOH), 8.40 (s, 1H,  $CHNO$ ), and 2.50 ppm (s, 3H,  $CH_3$ ). Analysis: C, H, N.

### 4-Methyl-1,2,5-oxadiazol-3-yl Hydroxyimoyl Chloride (4b)

To 3-hydroxyiminomethyl-4-methyl-1,2,5-oxadiazole (2b) (230 mg, 1.8 mmol) dissolved in 15 mL of dimethylformamide was added with stirring 240 mg (1.8 mmol) of N-chlorosuccinimide. The resulting mixture was stirred at room temperature for 20 min and 15 mL of HCl gas was bubbled into the reaction mixture. After 30 min the reaction mixture was heated to 50°C and allowed to slowly cool for 40 min. At the end of the 90-min reaction time the mixture

was poured into 60 mL of water. The aqueous solution was extracted with two 50-mL portions of diethyl ether, the combined ether extracts were washed with three 50-mL portions of water, dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated; yielding 280 mg (96%) of the crude hydroximoyl chloride. NMR showed an approximate 80% conversion to the desired hydroximoyl chloride product. NMR (CDCl<sub>3</sub>), δ 12.10 (s, 1H, NOH), and 2.50 ppm (s, 3H, CH<sub>3</sub>). This material was used without further purification.

4-Methyl-1,2,5-oxadiazol-3-ylthiohydroximic acid 2-(Diethylaminoethyl S-ester Hydrochloride (3b)

To the 230 mg (1.4 mmol) of hydroximoyl chloride prepared above and dissolved in 50 mL chloroform was added 240 mg (1.4 mmol) of diethylaminoethanethiol hydrochloride and 290 mg (2.8 mmol) of triethylamine. The resulting mixture was stirred overnight, then washed with two 50-mL portions of water, dried over anhydrous MgSO<sub>4</sub>, filtered, and solvent removed, yielding 350 mg of viscous yellow oil. NMR indicated that the majority of the crude reaction mixture was the desired product 3b contaminated with the starting material 2b. This mixture was chromatographed on 125 g of silica gel using a diethyl ether eluent; like fractions were combined and concentrated after TLC examination, yielding 150 mg (41%) of the free amine 3b as a clear oil. The hydrochloride salt of 3b was prepared by dissolving the above oil in 25 mL diethyl ether and adding dropwise an ethereal solution saturated with HCl gas. White crystals of the hydrochloride precipitated from solution. The crystals were filtered, and dried under vacuum, yielding 170 mg of analytically pure 3b hydrochloride; m.p. 121-122°C. NMR (DMSO-d<sub>6</sub>), δ 13.14 (s, 1H, NOH), 3.20 (m, 8H, CH<sub>2</sub>) and 1.22 ppm, (t, 6H, CH<sub>3</sub>). Analysis: C, H, N, S, Cl.

1,4-Diphenyl-5-hydroxyiminomethyl-1,2,3-triazole (2c)

Phenyl azide<sup>36</sup> (12.0 g, 0.10 mol) and phenylpropargyl aldehyde (12.5 g, 0.1 mol) were added to 65 mL toluene and refluxed overnight. The solvent was removed and the intermediate 1,4-diphenyl-5-formyl-1,2,3-triazole (7d) was separated and purified from the isomeric 1,5-diphenyl-4-formyl-1,2,3-triazole (7e) by silica gel chromatography with 4:1 CH<sub>2</sub>Cl<sub>2</sub>:30-60°C petroleum ether eluant. Subsequent treatment of 7d with one equivalent of hydroxylamine hydrochloride and recrystallization from CH<sub>3</sub>OH per the method of Sheehan and Robinson<sup>35</sup> yielded 1.5 g (5%) of 2c. NMR (DMSO-d<sub>6</sub>), δ 12.10 (br, s, 1H, NOH); 8.22 (s, 1H, CHNOH); 7.88 (m, 2H, phenyl) and 7.60 ppm (m, 8H, phenyl). IR (KBr) 3000 (br, s), 1580 (m), 1480 (s), 1440 (s), 970 (s) and 825 (s) cm<sup>-1</sup>. Analysis for C<sub>15</sub>H<sub>12</sub>N<sub>4</sub>O. Calc'd: C, 68.17; H, 4.58; N, 21.20. Found: C, 68.05; H, 4.53; N, 20.53.

1,4-Diphenyl-1,2,3-triazol-5-yl hydroximoyl chloride (4c)

1,4-Diphenyl-5-hydroxyiminomethyl-1,2,3-triazole, 2c (1.07 g, 4 mmol) dissolved in 30 mL of dimethylformamide was treated with 0.54 g (4 mmol) of N-chlorosuccinimide. Reaction and workups, similar to those described for 4a, yielded 1.07 (90%) of a white crystalline material; m.p. 164-168°C. The crude reaction product was assigned the hydroximoyl chloride structure 4c based upon the following; NMR (DMK-d<sub>6</sub>), δ 12.53 (s, 1H, NOH), 7.95 (m, 2H, phenyl) and

7.60 ppm (m, 8H, phenyl). Analysis for  $C_{15}H_{11}N_4Cl$ ; Cal'd: C, 60.30; H, 3.69; N, 18.76; Cl, 11.89. Found: C, 61.50; H, 3.93; N, 18.45; Cl, 10.13.

1,4-Diphenyl-1,2,3-Triazol-5-yl Thiohydroximic Acid 2-(Diethyl amino)ethyl S-Ester (3c)

Treatment of hydroximoyl chloride 4c with diethylaminoethanethiol hydrochloride as described previously for 4a and 4b, yielded 0.50 g of crude 3c. Recrystallization from 95% ethanol yielded 0.38 g (24%) of analytically pure 3c; m.p. 152-155°C; NMR (DMSO-d<sub>6</sub>), δ 12.58 (s, 1H, NOH) 7.92 (m, 2H, phenyl), 7.67 (m, 8H, phphenyl), 2.20 (m, 8H, CH<sub>2</sub>) and 0.70 ppm (t, 6H, CH<sub>3</sub>). Analysis: C, H, N, S.

1,5-Diphenyl-4-hydroxyiminomethyl-1,2,3-triazole (2d)

Compound 2d was prepared from the corresponding aldehyde 7e as described above for 2c. Recrystallization from 95% C<sub>2</sub>H<sub>5</sub>OH yielded 3.1 g (10%) of the desired material. NMR (DMSO-d<sub>6</sub>), δ 11.4 (s, 1H, NOH); 8.16 (s, 1H, CHNOH), and 8.20 ppm (m, 10H, phenyl). IR (KBr), 3175 (s), 1480 (s), 980 (s), 830 (s), 755 (s) and 680 (s) cm<sup>-1</sup>. Analysis: C, H, N.

1,5-Diphenyl-1,2,3-Triazol-4-yl Hydroximoyl Chloride (4d)

4-Hydroxyiminomethyl-1,5-diphenyl-1,2,3-triazole, 2d, (2.64 g, 10 mmol) was dissolved in 50 mL dimethylformamide with stirring while N-chlorosuccinimide (1.34 g, 10 mmol) was added. The resulting mixture was stirred 15 min followed by bubbling 15 mL of HCl gas through the solution. The solution was stirred an additional 15 min, heated to 55°C and allowed to cool slowly to ambient temperature (about one hr). The resulting mixture was poured into 200 mL water and extracted with two 100-mL portions of ether. The ether extracts were combined, washed with three 100-mL portions water, dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated, yielding 2.76 g (92%) of a white crystalline compound; m.p. 179-184°C. The solid material was assigned the hydroximoyl chloride structure 4d based upon the following: NMR (DMK-d<sub>6</sub>), δ 11.25 (s, 1H, NOH) and 7.38 ppm (m, 10H, C<sub>6</sub>H<sub>5</sub>). Analysis for  $C_{15}H_{11}N_4Cl$ : Calc'd: C, 60.30; H, 3.69; N, 18.76; Cl, 11.89. Found: C, 61.18; H, 3.72; N, 18.81; Cl, 10.15.

1,5-Diphenyl-1,2,3-Triazol-4-yl Thiohydroximic Acid 2-(Diethyl amino)ethyl S-Ester (3d)

The hydroximoyl chloride 4d (2.69 g, 9.0 mmol) in 75 mL of chloroform was treated with 1.48 g (9.0 mmol) of diethylaminoethanethiol hydrochloride and 6 mL of triethylamine (excess) and the resulting solution stirred overnight. Concentrating the crude reaction solution on the rotary evaporator yielded 3.18 g of a white crystalline product. The crude precipitate was triturated with a 60% ethanol/40% water solution and filtered. The precipitate was dried over P<sub>2</sub>O<sub>5</sub> yielding 2.94 g (83.0%). Two recrystallizations from a 75% chloroform/25% methanol solution yielded analytically pure 3d; NMR (DMSO-d<sub>6</sub>), δ 12.13 (br, s, 1H, NOH) 7.48 (m, 10H, phenyl), 2.55 (m, 9H, CH<sub>2</sub>) and 0.89 ppm (t, 6H, CH<sub>3</sub>). Analysis: C, H, N, S.

### 4-Formyl-1-phenyl-1,2,3-triazole (7f)

To 5.0 g (28.5 mmol) of 4-hydroxymethyl-1-phenyl-1,2,3-triazole (prepared by the cycloaddition of 2-propyn-1-ol with 1 equivalent of phenyl azide,<sup>38</sup>) was added a 0.5M solution of ceric ammonium nitrate (32.9 g, 2.1 equivalents) in 120 mL water. The reaction mixture was heated to 75°C for 90 min, cooled, and extracted with three 100-mL portions of diethyl ether. The combined ether extracts were washed with two 100-mL portions of a 1 N NaHCO<sub>3</sub> solution, dried over anhydrous MgSO<sub>4</sub>, filtered and the solvent was removed yielding light yellow crystals of the crude aldehyde. Column chromatography of the crude aldehyde on silica-gel using a methylene chloride eluent yielded, after removal of solvent, 1.77 g (35.4%) of analytically pure aldehyde, m.p. 97-99°C (Lit. m.p. 99-100°C).<sup>36</sup> Analysis: C,H,N.

### 4-Hydroxyiminomethyl-1-phenyl-1,2,3-triazole (2e)

4-Formyl-1-phenyl-1,2,3-triazole (7f) (1.79 g, 10.2 mmol) dissolved in 150 mL of absolute ethanol was treated with 0.77 g, one equivalent, of hydroxyamine hydrochloride and 0.81 g pyridine. The resulting mixture was refluxed for 2 h, the ethanol evaporated, and the residue taken up in 150-mL diethyl ether. The ether was washed with two 100-mL portions water, followed by the addition of 100 mL of diethyl ether saturated with HCl gas to remove residual pyridine. Subsequent washing with two additional 100-mL portions of water, drying over anhydrous MgSO<sub>4</sub>, filtering and solvent removal yielded 750 mg of a white crystalline product. The material was recrystallized twice from 95% ethanol yielding 550 mg (29%) of an analytically pure sample of 2e; m.p. 171-173°C. NMR (DMSO-d<sub>6</sub>), δ 12.17 (s, 1H, NOH), 9.24 (s, 1H, CHNO), 7.98 (m, 2H, phenyl), 7.88 (s, 1H, triazolyl) and 7.55 ppm (m, 3H, phenyl). Analysis: C,H,N.

### 1-Phenyl-1,2,3-triazol-4-yl Hydroximoyl Chloride (4e)

To 2e (250 mg, 1.3 mmol) dissolved in 15 mL of diethylformamide, 180 mg (1.3 mmol) of N-chlorosuccinimide was added. After 20 min stirring the solution was heated to 50°C and allowed to cool; then 10 mL of HCl gas, was bubbled into the reaction mixture. After 20 min additional stirring the crude reaction mixture was poured into 60 mL ice-water. Extraction with two 40-mL portions of diethyl ether followed by washing the combined ethereal extracts with three 50-mL portions of water, drying over anhydrous MgSO<sub>4</sub>, filtering and concentrating, yielded 260 mg (89%) of a white crystalline product. NMR showed essentially quantitative conversion to the desired hydroximoyl chloride product. NMR (CDCl<sub>3</sub>), δ 11.53 (s, 1H, NOH); 8.8 (s, 1H, CH triazolyl), 7.85 (m, 2H, phenyl) and 7.50 ppm (m, 3H, phenyl). This material was used without further purification.

### 1-Phenyl-1,2,3-triazol-4-yl Thiohydroximic Acid 2-(Diethyl amino)ethyl S-Ester (3e)

To 260 mg (1.2 mmol) of 4e, prepared above and dissolved in 50 L chloroform, was added 0.20 g diethylaminoethanethiol hydrochloride and 0.5 g (excess) triethylamine. The resulting mixture was stirred for two hours, then

washed with two 50-mL portions of water. A solid that remained suspended in the chloroform solution dissolved after the addition of 50 mL of diethyl ether. The mixture was dried over anhydrous  $MgSO_4$ , filtered and concentrated, yielding 170 mg (44%) of a white crystalline compound. The crude product was recrystallized twice from petroleum ether (30–60°C) yielding off-white needles of 3e; m.p. 241–243°C. NMR ( $DMSO-d_6$ ),  $\delta$  9.15 (s, 1H, CH, triazolyl), 7.95 (m, 2H, phenyl), 7.60 (m, 3H, phenyl), 2.90 (m, 2H,  $CH_2$ ), 2.33 (m, 6H,  $CH_2$ ) and 0.80 ppm (t, 6H,  $CH_3$ ). Analysis for  $C_{15}H_{20}N_5OS$ . Cal'd: C, 56.60; H, 6.29; N, 22.01; S, 10.06. Found: C, 55.41; H, 6.00; N, 23.02; S, 7.52.

#### 3-Bromomethyl-1,2,5-thiadiazole

In a 250-mL round bottom flask was placed 15.30 g (15.3 mmol) of 3-methyl-1,2,5-thiadiazole (7g) 29.96 g (16.8 mmol) of N-bromosuccinimide, 0.4 g benzoyl peroxide, and 150 mL carbon tetrachloride and the reaction mixture was refluxed overnight. The crude reaction mixture was washed with two 75-mL portions of 1 N sodium thiosulfate and with two 50-mL portions of water. The resulting solution was dried over anhydrous  $MgSO_4$ , filtered, and solvent evaporated, yielding 20.57 g of crude product. An NMR of the product showed a mixture of starting material, plus mono-, di-, and tribromo-substituted products formed during the reaction in a ratio of 15:50:25:10, respectively. This crude product was used in subsequent reactions without further purification. NMR ( $CDCl_3$ ),  $\delta$  8.63 (s, 1H, CH) and 4.72 ppm (s, 2H,  $CH_2Br$ ).

#### 3-Hydroxymethyl-1,2,5-thiadiazole

The crude 3-bromomethyl-1,2,5-thiadiazole (prepared above) was treated with 20 g potassium carbonate and 150 mL water. The resulting mixture was heated to 100°C and stirred for 90 min. The crude reaction mixture was then saturated with sodium chloride and extracted with three 100-mL portions of diethyl ether. The combined ethereal extracts were dried over anhydrous  $MgSO_4$ , filtered and concentrated, yielding 5.25 g of the desired alcohol, contaminated with a small quantity of the dibromo compound. NMR ( $CDCl_3$ ),  $\delta$  8.60 (s, 1H, CH), 4.92 (br. s, 2H,  $CH_2$ ) and 4.95 ppm (br, s, 1H, OH).

#### 3-Formyl-1,2,5-thiadiazole

3-Hydroxymethyl-1,2,5-thiadiazole (5.25 g, 45 mmol) was treated with 52 g of ceric ammonium nitrate dissolved in 190 mL of water. The resulting solution was heated to 75°C for 45 min and the crude reaction mixture extracted with two 50-mL portions of diethyl ether. The combined ether extracts were dried over anhydrous  $MgSO_4$ , filtered, and solvent removed, yielding the desired aldehyde. Isolation of the aldehyde proved difficult because the material was volatile and codistilled with ether. As a result of this volatility the aldehyde was converted to the desired oxime without isolation. NMR ( $CDCl_3$ ),  $\delta$  10.25 (2, 1H,  $C(O)H$ ) and 9.10 ppm (s, 1H, CH).

#### 3-Hydroxyiminomethyl-1,2,5-thiadiazole (2f)

In a 1 L flask was placed approximately 5.7 g (50 mmol) of crude 3-formyl-1,2,5-thiadiazole in 200 mL diethyl ether, 3.5 g (50 mmol)

hydroxylamine hydrochloride, 3.9 g pyridine and 500 mL absolute ethanol. The resulting mixture was refluxed overnight, concentrated, and then taken up in 200 mL diethyl ether. The ethereal solution was washed with two 150-mL portions of 1 H HCl followed by two 150-mL portions of water, dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated, yielding 1.05 g (16%) of 2f as a white crystalline material. The NMR of the crude product was consistent with an assigned structure of the E- and Z-aldoximes (see above).

Recrystallization from 25% diethyl ether/75% petroleum ether (30-60°C) yielded an analytically pure sample of the mixed E- and Z-aldoximes; m.p. 148-149°C NMR (DMSO-d<sub>6</sub>); z-aldoxime (major component), δ 12.10 (s, 1H, NOH), 9.12 (s, 1H, CHNO), and 8.43 ppm (s, 1H, CH); E-aldoxime (minor component), δ 12.53 (s, 1H, NOH), 9.50 (s, 1H, CHNO), and 7.95 ppm (s, 1H, CH). Analysis; C, H, N, S.

#### 1,2,5-Thiadiazol-3-yl Hydroximoyl Chloride (4f)

Aldoxime 2f (160 mg, 1.1 mol) dissolved in 15 mL dimethylformamide was treated with N-chlorosuccinimide (160 mg, 1.1 mmol). Reaction and workup identical to those described previously for 4a yielded 190 mg (100%) of the desired hydroximoyl chloride. NMR (DMK-d<sub>6</sub>), δ 12.07 (s, 1H, NOH), and 9.00 ppm (s, 1H, CH). This material was converted to 3f without further purification or characterization.

#### 1,2,5-Thiadiazol-3-yl thiohydroximic acid 2-(Diethylamino)ethyl S-Ester (3f)

To 190 mg (1.1 mmol) of 4f prepared above in (50 mL of chloroform) was added 210 mg (1.1 mmol) of diethylaminoethanethiol hydrochloride and 250 mg (2.2 mmol) of triethylamine. The reaction mixture was stirred for 2.5 h then washed with two 100-mL portions of water, dried over MgSO<sub>4</sub>, filtered and concentrated, yielding a yellow oil.

The oil slowly solidified, was triturated with diethyl ether, and filtered, yielding 55 mg (19%) of 3f as white crystalline material; m.p. 122-124°C. An analytical sample of 3f was obtained by column chromatography of the ethereal residue on silica-gel using a diethyl ether eluant. Like fractions were combined and concentrated after TLC examination. NMR (DMK-d<sub>6</sub>), δ 9.07 (s, 1H, CH), 2.10 (m, 2H, SCH<sub>2</sub>), 2.50 (m, 6H, CH<sub>2</sub>) and 0.95 (t, 6H, CH<sub>3</sub>). Analysis for C<sub>9</sub>H<sub>16</sub>N<sub>4</sub>S<sub>2</sub>: Cal'd: C, 41.54; H, 6.15; N, 20.77. Found: C, 41.13; H, 6.26; N, 21.62.

#### 3-Bromomethyl-4-methyl-1,2,5-thiadiazole\*

The subject material was prepared in a manner similar to that described above for 3-bromomethyl-1,2,5-thiadiazole. An NMR of the crude reaction product showed a mixture of starting material and monobromide, with an

\*Caution: 3-Bromomethyl-4-methyl-1,2,5-thiadiazole is a severe lacrymator and should be handled accordingly.

approximate 60% conversion. The material was converted to the alcohol without further characterization. NMR ( $\text{CDCl}_3$ ),  $\delta$  4.55 (2, 2H,  $\text{CH}_2\text{Br}$ ) and 2.50 ppm (s, 3H,  $\text{CH}_3$ ).

#### 3-Hydroxymethyl-4-methyl-1,2,5-thiadiazole

The crude monobromide, described above, was treated as described previously for 3-bromomethyl-1,2,5-thiadiazole with potassium carbonate in water at 90°C, yielding the crude monoalcohol contaminated with only small quantities of the dibromide. NMR ( $\text{CDCl}_3$ ),  $\delta$  4.80 (br, s, 3H,  $\text{CH}_2\text{OH}$ ), and 2.50 ppm (s, 3H,  $\text{CH}_3$ ). The material was oxidized to the corresponding aldehyde without further purification.

#### 3-Formyl-4-methyl-1,2,5-thiadiazole

The crude monoalcohol (12.75 g, 0.1 mmol) was treated with 104 g, 2.1 equivalents of ceric ammonium nitrate dissolved in 400 mL of water. Reaction and workup, as described for the previously prepared aldehydes, yield the volatile aldehyde. Because of the aldehyde's volatility it was converted to the desired oxime without isolation. NMR ( $\text{CDCl}_3$ ),  $\delta$  10.27 (s, 1H, C(O)H) and 2.80 ppm (s, 3H,  $\text{CH}_3$ ).

#### 3-Hydroxyiminoethyl-4-methyl-1,2,5-thiadiazole (2g)

In a 1 L flask was placed 6.4 g (50 mmol) of the freshly prepared aldehyde described above in 225 mL diethyl ether, 3.5 g (50 mmol) hydroxylamine hydrochloride 3.9 g pyridine and 500 mL of absolute ethanol. The resulting mixture was refluxed for two h, and the solvent was evaporated. The residue was dissolved in 75 mL of diethyl ether, the ether washed with two 150-mL portions of 1N HCl followed by 150 mL of water. The ethereal solution was dried over  $\text{MgSO}_4$ , filtered and concentrated to yield crystalline 2g. An analytical sample was obtained by repeated recrystallization from a 1:1 petroleum ether (30-60°C)/diethyl ether mixture; m.p. 131-134°C. NMR (DMSO- $d_6$ ),  $\delta$  12.05 (s, 1H, NOH), 8.48 (s, 1H, CH), and 2.73 (s, 3H,  $\text{CH}_3$ ). Analysis: C,H,N,S.

#### 4-Methyl-1,2,5-thiadiazol-3-yl Hydroximoyl chloride (4g)

A 1.73 g (12 mmol) sample of 2g, prepared above, dissolved in 60-mL diethylformamide was treated with 1.62 g (12 mmol) of N-chlorosuccinimide. The hydroximoyl chloride 4g was obtained in a manner similar to that described for the previous hydroximoyl chlorides. The NMR indicated an approximate 85% conversion to the hydroximoyl chloride. NMR (DMK- $d_6$ ),  $\delta$  12.88 (s, 1H, NOH) and 2.80 ppm (s, 3H,  $\text{CH}_3$ ). The material was converted to 3g without further purification.

#### 4-Methyl-1,2,5-thiadiazol-3-yl Thiohydroximic acid 2-(Diethyl amino)ethyl S-Ester hydrochloride (3g)

To 1.55 g (8.7 mmol) of 4g prepared above, in 75 mL of chloroform was added 1.48 g (8.7 mmol) diethylaminoethanol hydrochloride and 1.76 g

(17.4 mmol) of triethylamine (two equivalents), and the resulting solution was stirred overnight. The crude reaction mixture was then washed with 100 mL of water, dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated. TLC examination of the residue (diethyl ether eluent on silica-gel) indicated three components. The crude material was purified on 125 g of silica-gel using a 100% diethyl ether eluant. The first fraction proved to be 2g; NMR and melting point were identical to authentic sample. The second fraction, 0.93 g (39%) of a yellow oil, proved to be the free amine of the desired 3g. The hydrochloride salt of 3g was prepared by dissolving the above oil in 25 mL of diethyl ether and adding dropwise an ethereal solution saturated with HCl gas. Upon addition of the ethereal HCl, white crystals of the hydrochloride salt 3g precipitated. After saturation, the white crystals were filtered and dried under vacuum, yielding 0.98 g of analytically pure 3g; m.p. 179-182°C. NMR (DMSO-d<sub>6</sub>), δ 12.72 (s, 1H, NOH), 3.18 (m, 9H, CH<sub>2</sub>), 2.63 (s, 3H, CH<sub>3</sub>) and 1.10 ppm (t, 6H, CH<sub>3</sub>). Analysis: C, H, N, S, Cl.

#### AChE Reactivation

Ethyl p-nitrophenyl methylphosphonate was added to a slight excess of electric eel AChE in pH 7.6, 0.1 M morpholinopropane sulfonic acid buffer, and NaN<sub>3</sub> (0.002%), MgCl<sub>2</sub> (0.01 M), and bovine serum albumin (0.01%). Aliquots of ethyl methylphosphonyl-AChE were diluted into buffer solution containing reactivators at various concentrations, and incubated for timed intervals before withdrawing aliquots and assaying for activity by the method of Ellman.<sup>39</sup> All experiments were performed at 25 ± 0.5°C. Rate constants were determined by linear least-squares regression analysis of the data and error limits reported as standard deviations. Details of the method have been previously described.<sup>23</sup>

#### LITERATURE CITED

1. Heath, D. F. Organophosphorus Poisons—Anticholinesterases and Related Compounds Pergamon Press, New York, 1961.
2. Spear, R. C.; Jenkins, D. L.; Milby, T. H. Environ. Sci. Technol., 1975, 9, 308-313.
3. Milby, T. H., J. Am. Med. Assoc., 1971, 216, 2131-2133.
4. Koller, W. C.; Klawans, H. L., Handb. Clin. Neurol., 1979, 37, 541-62.
5. Baker, E. L.; Warren, Mc.; Zack, M.; Dobbin, R. D.; Miles, J. W.; Miller, S.; Alderman, L.; Teeters, W. R. Lancet, 1978, 1, 31-4.
6. Koelle, G. B. chapter 22 in "Anticholinesterase Agents," The Pharmacological Basis of Therapeutics, L. Goodman and A. Gilman (eds.), MacMillan, New York, 1965; pp. 404-444.
7. Sim, V. M. chapter 60 in "Chemicals Used as Weapons in War," Drill's Pharmacology in Medicine, 3d ed., McGraw-Hill, New York, 1965; pp. 971-982.
8. Harris, B. L.; Shanty, F.; Wiseman, W. J. Kirk-Othmer Encycl. Chem. Technol. 3d ed., Vol. 5, J. Wiley and Sons, New York, 1980; pp. 393-416.
9. Meselson, M; Robinson, J. P. Sci. Amer., 1980, 242 39-47.
10. "CB Weapons Today," Vol. 2 in The Problems of Chemical and Biological Warfare, Stockholm International Peace Research Institute, Humanities Press, New York, 1973; pp. 17-115.
11. Karczmar, A. G. Int. Encycl. Pharmacol. Ther., 1970, 1(13), 1-40.
12. Usdin, E. Int. Encycl. Pharmacol. Ther., 1970, 1(13), 47-356.
13. Englehard, N.; Prhal, K.; and Nenner, M. Angew. Chem. Internat. Ed., 1967, 6, 615-626.
14. We use the term "phosphylation" when we do not distinguish between "phosphonylation" and "phosphorylation".
15. Wills, J. H. Int. Encycl. Pharmacol. Ther. 1970 1(13), 357-469.
16. Namba, T.; Nolte, C. T., Jackrel, J.; Grob, D. Am. J. Med., 1971, 50, 475-492.

17. Ellin, R. I.; Wills, J. H. *J. Pharmaceut. Sci.*, 1964, 53, 995-1007.
18. McNamara, B. P., "Oximes As Antidotes in Poisoning by Anticholinesterase Compounds," Edgewood Arsenal Special Publication 5B-SP-76004.
19. Hobbiger, F.; Vojvodic, V. *Biochem. Pharmacol.*, 1967, 16, 455-462.
20. Milosevic, M. P.; Andjelkovic, D., *Nature (Lond.)*, 1966, 210 206.
21. Bajgar, J.; Jakl, A.; Hrdina, V. *Biochem. Pharmacol.*, 1971, 22 3230-3233.
22. Kenley, R. A.; Howd, R. A.; Mosher, C. W.; Winterle, J. S. *J. Med. Chem.*, 1981, 24, 1124-1133.
23. Kenley, R. A.; Bedford, C. D.; Howd, R. A.; Jackson, S.; Mosher, C. W. Part I of this Report.
24. Albert, A.; Sergeant, E. P. Ionization Constants of Acids and Bases, J. Wiley and Sons, Inc., New York, 1962.
25. Benschop, H. P.; van den Berg, G. R.; Van Hooidonk, C.; De Jong, L.P.A.; Kientz, G. E.; Berends, F.; Kepner, L. A.; Meeter, E.; Visser, R.P.L.S. *J. Med. Chem.*, 1979, 22, 1306-1313.
26. Kleinspehn, G. G.; Jong, J. A.; Studniare, S. A. *J. Org. Chem.*, 1967, 32, 460-462.
27. Benschop, H. P.; Van Oosten, A. M.; Platenburg, D.H.J.M.; Van Hooidonk, C. *J. Med. Chem.*, 1970, 13, 1208-1212.
28. Poziomek, E. J.; Kramer, D. N.; Fromm, B. W.; Mosher, W. A.; *J. Org. Chem.*, 1961, 26, 423-427.
29. Poziomek, E. J.; Kramer, D. N.; Mosher, W. A.; Michel, H. O. *J. Am. Chem. Soc.*, 1961, 83, 3918-3917.
30. Kitz, R. J.; Ginsburg, S.; Wilson, I.B. *Biochem. Pharmacol.*, 1965, 14, 1471-1477.
31. Smolikova, J.; Exner, O.; Barbaro, G.; Macciantelli, D.; Dondoni, A. *J. Chem. Soc. Perkin II*, 1980, 1051-1056.
32. Stolle, R. *Chem. Ber.*, 1899, 32, 797.
33. Behr, L. C.; Brent, J. T. Organic Synthesis Coll. Vol IV, John Wiley, and Sons, New York, 1963, p. 342.
34. Micetich, A. *Can. J. Chem.*, 1970, 48, 2012.
35. Sheehan, J. C.; Robinson, C. A. *J. Am. Chem. Soc.*, 1951, 73, 1207.

36. Hottel, R. Chem. Ber., 1941, 24B, 1680.
37. Weinstock, L. M.; Davis, P.; Handelman, B.; Tull, R. J. Org. Chem., 1967, 32, 2823.
38. Lindsay, R. O.; Allen, C.F.H., Organic Synthesis Coll. Vol. III, John Wiley and Sons, New York, 1955, p. 710.

## DISTRIBUTION LIST

12 copies

Director  
Walter Reed Army Institute of Research  
Walter Reed Army Medical Center  
ATTN: SGRD-UWZ-C  
Washington, DC 20307-5100

4 copies

Commander  
US Army Medical Research and Development Command  
ATTN: SGRD-RMS  
Fort Detrick, Frederick, Maryland 21701-5012

12 copies

Defense Technical Information Center (DTIC)  
ATTN: DTIC-DDAC  
Cameron Station  
Alexandria, VA 22304-6145

1 copy

Dean  
School of Medicine  
Uniformed Services University of the  
Health Sciences  
4301 Jones Bridge Road  
Bethesda, MD 20814-4799

1 copy

Commandant  
Academy of Health Sciences, US Army  
ATTN: AHS-CDM  
Fort Sam Houston, TX 78234-6100

**END**

**FILMED**

**9-85**

**DTIC**